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Abstract 
Objective – A previous pilot study had shown that there 
was potential to extend the roles of advanced biomedical 
scientist practitioner (ABMSPs) now referred to as 
Consultant Biomedical Scientists (BMS) to report the 
histology of large loop excision biopsies of the cervical 
transformation zone (LLETZ) within the NHS Cervical 
Screening Programme (NHSCSP). 
Methods - 157 consecutive LLETZ specimens reported by 
four experienced Gynae-specialist Consultant 
Histopathologists at Sheffield Teaching Hospitals NHS 
Foundation Trust, were also reported by six Consultant 
BMS, and compared against the final issued report.  
Neoplastic abnormalities were reported to NHSCSP 
standards as well as the Bethesda system.  Completeness 
of excision and histological features associated with the 
presence of human papillomavirus (HPV) infection were 
also assessed.  The reporting of HPV is part of the proforma 
for reporting cervical samples, it does not affect the patient 
management but allows for correlation with the cervical 
cytology report and hence was included as part of the 
study.  
Results - There was overall good inter-observer agreement 
for both the three tier and two tier system of grading 
squamous lesions plus good agreement for glandular and 
invasive carcinomas identified by the Consultant BMS.  
There was variable inter-observer agreement for the 
completeness of the excision of the margins and the 
presence of HPV. 
Conclusions - This report provides evidence that suitably 
experienced Consultant BMS can be ‘fast-tracked’ through 
an approved training programme of selected specimens  to 
meet the needs of the Histopathology service that is facing 
a chronic shortage of Histopathologists in a timely manner 
and provide a cost-effective solution.  
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Introduction 
Over the last couple of decades, roles that were traditionally 
undertaken by the medical profession have been transferred to 
appropriately trained non-medically qualified practitioners in 
the National Health Service (NHS).  These roles have rapidly 
expanded in many areas of healthcare, notably nursing and 
diagnostic imaging (Sibbald et al, 2006).  In the field of 
radiography, radiographers who used to be known as x-ray 
technicians have taken on advanced practitioner roles that 
were traditionally undertaken by medical radiologists such as 
administering intravenous injections, barium enemas and 
reporting images e.g. mammography images (Price and Le 
Masurier, 2007: Nightingale and Hogg, 2003).  Advanced 
nurse practitioners (ANP) have been shown to be an important 
step in the pathway of patient care by assessing whether they 
need to see a doctor or can be treated by an ANP or another 
health professional.  The following definition of an ANP could 
also be applied and adapted to the role of the Consultant 
Biomedical Scientist (BMS) in cervical cytology and defines the 
ANP as “an advanced level clinical nurse who through extra 
education and training is able to practice autonomously, 
making clinical decisions and instigating treatment decisions 
based on those decisions, and is fully accountable for her own 
practice” (Royal College of Nursing, 1989).   
The Consultant BMS in cervical cytology has undergone extra 
training and is competent to practice independently once they 
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have passed their final exit examination – the Advanced 
Specialist Diploma in Cervical Cytology.    
Advanced roles in Healthcare Science  
The first advanced role in healthcare science was the advanced 
biomedical scientist practitioner (ABMSP) in cervical cytology 
now known as Consultant Biomedical Scientists (BMS).  
Consultant BMS in cervical cytology were first introduced in the 
year 2000 due to a chronic shortage of Consultant 
Histopathologists specialising in cervical cytology and quality 
concerns that were raised by incidents in the cervical screening 
programme in Kent and Canterbury (Prichard, 1996: Johnson 
and Patnick, 2000).  Consultant BMS were introduced to the 
NHS Cervical Screening Programme (NHSCSP) following 
acceptance by the Department of Health to a joint proposal 
from the Royal College of Pathologists (RCPath) and the 
Institute of Biomedical Science (IBMS) (The Royal College of 
Pathologists, 2000) and in line with ‘Making the Change – A 
Strategy for the Professions in Healthcare Science’ 
(Department of Health, 2001).     
The aim of this joint proposal was to extend the practice of 
senior experienced BMS to report abnormal cervical cytology 
samples and recommend patient management such as referral 
for colposcopy and early repeat of testing.  The Consultant 
BMS have the knowledge and experience to offer clinical advice 
to sample takers and to provide help/support for the cervical 
screening team in their laboratory.  In some hospitals, 
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Consultant BMS are expected to provide cervical cytology 
training for the junior medical pathologists, as well as training 
for non-medical staff.  They would also be expected to present 
their cases to the Colposcopy multidisciplinary team (MDT) 
meetings where any discrepant or mismatch cases would be 
discussed between the Colposcopy clinician, Histopathologists 
and Cytologists to determine the best way forward for the 
woman, whether that is further treatment, surveillance or 
discharge back to primary care.  As can be seen from the 
above, the new role of the Consultant BMS has an extensive 
role and is equivalent to a medically qualified pathologist but 
only in the area of cervical cytology.   
Recent best practice recommendations from the Royal College 
of Pathologists, has stated that Consultant BMS can be the 
clinical lead for the cervical screening service.  The clinical lead 
is defined as the individual ‘who takes overall responsibility for 
the clinical quality and governance of a service.’  Although 
everybody within the cervical screening department is 
responsible for ensuring quality and governance, the clinical 
lead as the name suggests has the ultimate responsibility for 
leading and giving direction (The Royal College of Pathologists, 
2019).   
Eligibility criteria and the training programme for BMS has 
modified over the years since the onset of the original 
examination in 2000 as the qualification has matured (Smith 
and Hewer, 2003: Symonds, 2003: Institute of Biomedical 
Science, 2018).   
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Suitable candidates must be state-registered with the Health 
and Care Professionals Council (HCPC) as a biomedical 
scientist, have at least seven years of primary cytology 
screening experience post NHSCSP Certificate of Competence 
or equivalent, be a Fellow or Member of the Institute of 
Biomedical Sciences (IBMS), have a minimum of three years 
as a ‘checker’ plus service management and a statement from 
the clinical lead supporting the candidate.  These candidates 
will undergo an approved training programme under the 
supervision of a Consultant pathologist practising cervical 
cytology.  On completion of their training portfolio, they have 
to pass the examination for the Certificate in Advanced 
Practice, now known as the Advanced Specialist Diploma (ASD) 
in Cervical Cytology, managed by the Conjoint Board of the 
RCPath and IBMS before they can be appointed to the 
reporting position of a Consultant BMS.  Since the start of the 
examination there have been more than 100 successful 
candidates with an overall pass rate of 57.5% (Wilson, 2019).   
There are a number of extended and advanced roles within 
healthcare science and pathology in the UK that were 
traditionally performed by medically qualified pathologists that 
are now undertaken by biomedical scientists.  These have 
followed on from the successful introduction of the Consultant 
BMS in cervical cytology employed by laboratories providing 
screening for the NHSCSP.  For suitably experienced BMS there 
are four more ASDs available in Ophthalmic Pathology, 
Specimen Dissection, Non-Gynaecological Cytology and 
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Histopathology Reporting (Institute of Biomedical Science, 
2019).  These changes have been driven partly by pathology 
reviews and workforce reviews to address the national 
shortage of pathologists (Department of Health, 2004). 
Following on from the successful introduction of the Consultant 
BMS in cervical screening departments in the UK, other 
countries are looking to introduce advanced roles for their 
scientific staff most notably the cytotechnologist pathologist 
extender in the USA (Sweeney and Wilbur, 2018).  As the 
discipline of cervical cytology is changing world wide, 
alternative role are being developed for cytotechnologists such 
as the prescreening evaluation of fine needle aspirates (FNAs) 
and rapid on site evaluation (ROSE) of the adequacy of 
samples taken in clinics and microscopy interpretation of 
fluorescence in situ hybridization (FISH) (Cahill, 2014: 
Gonzalez et al, 2017).         
There are currently approximately 55 Consultant BMS in 
cervical screening with reporting roles in the UK and this 
number will reduce with their microscopic skills lost to the 
service as the changes continue with the way the NHSCSP 
delivers cervical screening.  The workloads in cervical 
screening services have reduced due to changes in NHS 
screening policies such as the introduction of liquid based 
cytology (LBC), Human Papillomavirus (HPV) testing and 
automation plus the onset of the HPV vaccinated cohort 
(National Institute for Health and Clinical Excellence (NICE), 
2003: Moss et al, 2004: Arbyn et al, 2005: Kitchener et al, 
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2009: Ronco et al, 2010: Murphy et al, 2012: Cuzik et al, 
2010).  As the vaccinated cohort enters the cervical screening 
programme there will be further reductions in cervical disease 
(Kohli et al, 2007) and this has already been seen in the 
Scottish cervical screening programme (Palmer et al, 2019).  
This is further compounded by reductions in screening 
workloads due to the consolidation of laboratories from 46 to 
eight centres nationally with the introduction of HPV primary 
screening.   
As the scope for the Consultant BMS in cervical cytology is 
changing, in the background, pathology services are facing a 
chronic shortage of Histopathologists.  There are many 
vacancies for Consultant Histopathologists locally and this was 
corroborated in a survey by the Royal College of Pathologists 
in September 2018.  The survey confirmed that only 3% of 
histopathology departments have enough staff to meet the 
demands of their clinical service and approximately 25% of the 
workforce is over the age of 55 due to retire in the near future 
(Royal College of Pathologists, 2018).  Histopathologists are 
vital in the role of diagnosing diseases such as cancer and 
giving guidance to the clinician as to the best treatment 
pathways for their patients.  These shortages could contribute 
to delays in patient diagnosis and management.  A plan is in 
place to introduce new Histopathologists but this will take 
time, however by utilising the skills of Consultant BMS in 
selected areas such as cervical pathology, this should allow 
Histopathologists to concentrate on the more complex areas of 
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their workload in the interim period and should be more cost-
effective.   As stated earlier, there have been developments in 
extended roles for experienced BMS such as specimen 
dissection and non-gynaecological cytology.  The help of the 
BMS in these extended roles has been met favourably by 
Histopathologists and have helped with their management of 
their workloads (Duthie et al, 2004: Simmons et al, 2011).   
It is important to understand the NHSCSP and how Consultant 
BMS have contributed to the success of the programme with 
their skills and specialised knowledge.  Consultant BMS have 
proved their extensive knowledge of cervical disease and the 
NHSCSP with the exit examination of the Advanced Specialist 
Diploma in cervical cytology.  As described earlier, the delivery 
of the NHSCSP has changed and will continue to develop with 
a loss of these highly motivated and specialist staff unless 
alternative roles can be found that will utilise their skills and 
knowledge.  The basis of this study is to evaluate how the 
skills of the Consultant BMS can be utilised further.  
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NHS Cervical Screening Programme (NHSCSP) 
Screening Programmes 
A medical screening programme tests the asymptomatic 
population for a disease that is a precursor of cancer such as 
the breast and cervical screening programmes.  The conditions 
for a successful screening programme for the World Health 
Organisation (WHO) were set by Wilson and Junger (Wilson 
and Junger, 1968). A disease which is suitable for screening as 
identified by Wilson and Junger should meet the following ten 
conditions 
1. The condition sought should be an important health 
problem 
2. There should be an accepted treatment for patients with 
recognised disease 
3. Facilities for diagnosis and treatment should be available 
4. There should be a recognisable latent or early 
symptomatic stage 
5. There should be a suitable test or examination 
6. The test should be acceptable to the population 
7. The natural history of the condition, including 
development from latent to declared disease, should be 
adequately understood 
8. There should be an agreed policy on whom to treat as 
patients 
9. The cost of case-finding (including diagnosis and 
treatment of patients diagnosed) should be economically 
balanced in relation to possible expenditure on medical 
care as a whole 
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10. Case-finding should be a continuing process and 
not a “once and for all” project 
The principles for screening have been updated to take in to 
account of recent screening developments (Andermann et al, 
2008) 
 The screening programme should respond to a 
recognised need 
 The objective of screening should be identified at the 
outset 
 There should be a defined target population 
 There should be scientific evidence of screening 
programme effectiveness 
 The programme should integrate education, testing, 
clinical services and programme management 
 There should be quality assurance, with mechanisms to 
minimise potential risks of screening 
 The programme should ensure informed choice, 
confidentiality and respect for autonomy 
 The programme should promote equity and access to 
screening for the entire target population 
 Programme evaluation should be planned from the 
outset 
 The overall benefits of screening should outweigh the 
harm 
Screening to prevent cervical cancer follows the above 
principles for a screening programme as cervical intraepithelial 
neoplasia (CIN) is the recognised precursor stage for cervical 
cancer which can be identified with cervical cytology.   
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As we continue to understand how cervical cancer develops, it 
has been recognised that women have to be exposed to ‘high 
risk’ HPV by skin-to-skin contact and once integrated in to the 
DNA of cervical cells causes over 99% of cervical cancers 
(Walboomers et al, 1999: Bosch et al, 2002).  Over 80% of 
women will come into contact with HPV, however most of them 
will clear the infection within two years.  Some women are 
unable to clear the HPV infection, known as persistence and 
together with other factors such as immunodeficiency, 
smoking and sexual activity are at higher risk of developing 
cervical cancer (Burd, 2003).  Cervical cancer can take up to 
20 years to develop from the first exposure to HPV developing 
in to CIN and becoming invasive (Sherris et al, 2001).   
Cervical screening can detect these early stages of cervical 
cancer by using HPV testing and cytology.  This allows the 
woman to be diagnosed and treated before the disease which 
if left untreated may go on to develop in to cervical cancer 
(Denny, 2008).  We do not know which women who get 
diagnosed with cervical precancer will go on to develop cervical 
cancer, hence we have to treat them as the worst case 
scenario (McCredie et al, 2008).   
The cervical screening test on the whole is seen as an 
acceptable test following the WHO guidelines as it is a 
minimally invasive procedure and the sample can be taken in 
primary care.   Some women may disagree with this statement 
as they find attending for cervical screening embarrassing and 
some of them may find it to be an uncomfortable procedure 
(Waller et al, 2009).  These are just some examples of the 
barriers that are putting women off for attending cervical 
screening resulting in low coverage.  Coverage in 2013-14 was 
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74% and in 2016-17 was 72 % below the lower threshold of 
75% and well below the national target of 80% (Department of 
Health & Social Care, 2019).  The trend of coverage dropping 
continued in 2017-18 with the coverage rate at 71.4% (NHS 
Digital, 2018).   
‘The primary aim of the NHSCSP is to reduce both the 
incidence and mortality from cervical cancer by regularly 
screening all women so that conditions which might otherwise 
develop into invasive cervical cancer can be identified and 
treated at an early stage with a better prognosis.  Currently 
women are invited from the age of 25 to 49 years of age every 
three years and from 50 to 64 every five years to attend for 
cervical screening’ (Public Health England, 2015).  
The NHSCSP has been very successful since it was formally 
introduced in 1988 and it has been estimated that the NHSCSP 
has saved 4,800 women per year from dying of cervical cancer 
in the UK (Peto et al, 2004).  
Cervical Screening Test 
In England, women are invited to attend for cervical screening 
every three to five years where a sample is taken from the 
cervix at the area where the epithelium changes from the 
multi-layered ectocervical epithelium to the monolayer 
endocervical epithelium known as the transformation zone.  
The transformation zone is represented in Figure 1 and in the 
histological section of the cervix in Figure 2    
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Figure 1 Diagram of uterus and cervix to demonstrate 
sampling area 
 
 
Figure 2 Histological representation of epithelium of 
the cervix 
 
 Slide from own collection  
When the NHSCSP first commenced, cells were directly 
smeared on to a glass slide and fixed.  The slides were then 
Magnification x 40 
Courtesy of Johns Hopkins Medicine 
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sent to the laboratory for staining and microscopic 
examination.  This is where the term ‘cervical smear’ 
originates from.  The ‘cervical smear’ or ‘Pap test’ remained 
the same for over 50 years before new technology was 
introduced.  Once the slide is produced by whatever technique, 
the method of evaluation is fundamentally the same.  A 
cytologist looks down the microscope to critically evaluate the 
cells looking for changes which may indicate a cervical 
abnormality that needs further investigation (Figure 3). 
Normal and abnormal cells from the cervix were first described 
and drawn by George Papanicolaou who devised the term 
dyskaryosis (Papanicolaou and Traut, 1941: Papanicolaou, 
1963).  Dyskaryosis is derived from ‘dysk’ which is Greek for 
abnormal and ‘karyon’ is Greek for nut or nucleus.  In the UK, 
dyskaryosis is used to describe and grade the abnormality of 
cells from cervix (Denton et al, 2008).  The different cytology 
grades are listed in Table 1 with their corresponding 
histological grades of CIN, cervical glandular intraepithelial 
neoplasia (CGIN) and cancer.  In the rest of the world different 
terminology is used most notably The Bethesda System is used 
in the USA and extensively in Europe (Solomon, 2002: Nayar 
and Wilbur, 2014). 
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Figure 3 Images of normal and dyskaryotic cells 
 
 
 
 
Slides from own collection 
New techniques are always evaluated by the NHSCSP prior to 
introduction to the programme to ensure that they are as least 
as good as previous methods and are cost-effective.  Liquid 
based cytology (LBC) was a new technology and was 
introduced in to the NHSCSP on 2003 following the 
recommendation of the National Institute for Health and 
Clinical Excellence (NICE, 2003) plus the results of the pilot 
study (Moss et al, 2006).   
  
Severely dyskaryotic 
cells - abnormal 
Normal 
endocervical 
cells 
Normal 
squamous 
cells 
Magnification x 100 
 
Magnification x 400 
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Table 1 UK cytology terminology with corresponding 
histology terminology 
Previous 
terminology 
(BSCC 1986) 
New terminology 
(BSCC 2008) 
Histopathology  
terminology 
Inadequate  Inadequate N/A 
Negative Negative No CIN/ HPV changes 
only 
Borderline change 
Borderline change in 
squamous cells 
Corresponds to low 
grade CIN   
Borderline change in 
endocervical cells 
Possible low grade 
CGIN (classified as 
high grade histology) 
Mild dyskaryosis Low-grade dyskaryosis CIN 1 
Borderline change 
with koilocytosis 
Moderate 
dyskaryosis 
High-grade 
dyskaryosis 
(moderate) 
CIN 2 
Severe dyskaryosis High-grade 
dyskaryosis (severe) 
CIN 3 
Severe dyskaryosis, 
possibly invasive 
High-grade 
dyskaryosis/possible 
invasive squamous 
carcinoma 
Squamous cell 
carcinoma 
? Glandular 
neoplasia* 
? Glandular neoplasia 
of endocervical type* 
CGIN 
? Glandular neoplasia 
(non-cervical)* 
Non-cervical cancers 
e.g. endometrial 
* ? as expressed in front of glandular neoplasia is recognised 
terminology used by the NHSCSP suggesting that the lesion 
maybe derived from the glandular epithelium of the cervix 
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however it is not conclusive and may be from other parts of 
the female genital tract.    
Liquid based cytology (LBC) 
LBC is a technique where cells that have been sampled directly 
from the cervix are placed in a vial composed of alcohol with a 
blood-lysing agent.  The exact composition of the medium is 
protected by the trade names of ThinPrep® or SurePath™.  The 
vials are sent to the laboratory for processing on the ThinPrep® 
or SurePath™ platforms.  LBC lets the laboratory control the 
processing improving the quality of the sample ensuring that 
the final preparation is uniform, cleaner and a smaller area to 
screen (Moss et al, 2006).  There are many advantages to 
using LBC such as the preparations are cleaner and quicker to 
screen with a reduction of inadequate rates from 9% to 1.6% 
(National Institute for Health and Clinical Excellence (NICE), 
2003: Gupta et al, 2016).  As there is residual material within 
the vial extra preparations can be made for teaching purposes 
and adjunctive tests can also be performed.  Adjunctive tests 
include HPV testing and molecular markers such as CINtec® 
PlusCytology.  CINtec® PlusCytology is a dual-biomarker that 
has a strong association with high grade cervical disease as 
p16 is a surrogate marker for HPV infection and Ki67 is a 
marker for cell proliferation (Wright et al, 2017).  These tests 
help by allowing the reporter to state whether the changes in 
the cells are more likely to be transient rather than to go on to 
develop to high grade disease. 
Human Papillomavirus (HPV)  
HPV comprises over a 100 sub-types of which 40 affect the 
female genital tract but it is the high-risk sub-types mainly 
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HPV 16 and 18 that are the principle cause of CIN – the 
premalignant changes found in the cervix and cervical cancer 
(Walboomers et al, 1999: Bosch et al, 2002).    
The NHSCSP always assesses new methodology to ensure this 
technology such as HPV testing, molecular markers and 
scanning techniques will improve the sensitivity and specificity 
of screening but still remains cost-effective. There have been 
many studies confirming that using HPV testing offers better 
sensitivity for the detection of precancerous changes and is 
able to identify women who may go on to develop cervical 
disease particularly if they have been diagnosed with a low 
grade cytological abnormality (Arbyn et al, 2005: Kitchener et 
al, 2009: Ronco et al, 2010: Murphy et al, 2012).  When 
reviewing the literature, it needs to be considered what the 
authors are basing their conclusions on as the clinical 
outcomes can be matched to CIN 2+ or CIN 3+ cut off which 
may bias the results in to looking more sensitive.      
As stated earlier, although the literature suggests that new 
tests in the cervical screening programme may be superior, 
the English programme will always assess new tests within the 
confines of the NHSCSP and with the overview of the Advisory 
Committee for Cervical Screening (ACCS).  The ACCS is 
comprised of experts covering all aspects of the English 
cervical screening programme including GPs, senior biomedical 
scientists, Consultant Histopathologists, Epidemiologists etc. 
that are accountable to the UK National Screening Committee 
(NSC).  The UK NSC provides guidance and advice to the 
Department of Health about all screening programmes in the 
four nations.  The NHSCSP pilots the new tests through six 
cervical screening laboratories (Bristol, Liverpool, London, 
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Manchester, Norwich and Sheffield) known as the sentinel sites 
and the results are evaluated to shape the future direction of 
the programme. 
The first pilot in 2008 looked at the implementation of HPV 
triage and test of cure (ToC) to evaluate whether this would 
work in the English screening programme.   The literature was 
suggesting that combining cytology and HPV tests should 
speed up the referral of women for colposcopy, reduce the 
number of re-tests, return women to normal recall earlier, 
avoid unnecessary referrals for colposcopy and is cost-effective 
(Manos et al, 1999: Legood et al, 2006).  Women who are not 
infected with high risk HPV are virtually at no risk of 
developing cervical cancer in the next ten years with a 
negative predicative value of just under 100% (Safaeian et, 
2007: Fröberg et al, 2008).  Women who are on annual follow 
up for ten years after treatment for cervical disease can be 
returned to normal recall if they are HPV/cytology negating all 
the anxiety of repeat cytology and reducing the time span of 
the patient pathway.   
As a result of this successful pilot, HPV triage and ToC was 
successfully rolled out nationally in 2011 (Department of 
Health, 2011). 
Human Papillomavirus (HPV) vaccination 
The Cancer Reform Strategy (Department of Health, 2007) 
announced that the HPV vaccination would be introduced to 
school girls from 2008 to protect them from the high risk HPV 
types 16 and 18 and significantly reduce their risk of 
developing cervical cancer.  This has now been expanded to 
include boys of school age too, to commence in September 
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2019 (Department of Health and Social Care, 2018).  Studies 
have shown that the introduction of the HPV vaccination may 
prevent up to 70% of cervical cancers from developing, 
however cervical screening will still be needed to detect 
premalignant changes for cancers which will not be prevented 
by the HPV vaccine (Muñoz et al, 2003: Howell-Jones et al, 
2010).  This means that vaccinated women will have less CIN 
which will decrease the sensitivity and specificity of cytological 
cervical screening with microscopic assessment - in other 
words, the less you see of the precursors for disease such as 
abnormal cells, the less likely you are able to identify them 
(Evered, 2010).  Due to this risk, alternative screening 
strategies will need to be developed and implemented before 
the first cohort of vaccinated women come through for 
screening hence why the NHSCSP has implemented HPV 
primary screening which is described next.  
HPV Primary Screening  
Following on from the successful introduction of HPV triage and 
ToC, the NHSCSP used the sentinel sites to evaluate the 
introduction of HPV primary screening.  The evaluation was 
based on the outcomes of four major European randomised 
trials including the English study ‘A Randomised Trial in 
Screening to Improve Cytology’ the ARTISTIC trial (Bulkmans 
et al, 2004; Naucler et al, 2007; Ronco et al, 2010, Kitchener 
et al, 2009 and Kitchener et al, 2009b).  The ARTISTIC trial 
showed HPV testing was more sensitive for the detection of 
cervical disease than cytology alone and a negative HPV test 
gave longer protection which may allow for screening intervals 
to be extended (Kitchener et al, 2009).  Further screening 
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rounds in the ARTISTIC trial demonstrated that the screening 
intervals could be extended and HPV primary screening would 
be more cost-effective (Kitchener et al, 2014) 
England was one of the first countries to introduce HPV 
primary screening.  With HPV primary screening the sample is 
taken in the same way with cells scraped from the surface of 
the cervix using the NHSCSP approved brush.  Depending on 
which LBC technology is used, the brush is left in the vial as 
with SurePath™ or with ThinPrep® the cells are deposited in 
the vial.  The change occurs at this stage, as the vial is tested 
for HPV first and if negative, the woman is returned to normal 
recall.  If the HPV test is positive, a slide is prepared for 
microscopic assessment.  If the cytology slide is negative, the 
test is repeated in 12 months and if positive i.e. abnormal cells 
found, the woman is referred for colposcopy for further 
assessment.  The HPV primary screening protocol is shown in 
Figure 4.  The results of the pilot sites demonstrated that HPV 
primary screening was acceptable to the programme.  The UK 
NSC recommended that HPV primary screening should be 
rolled out nationally and it was formally announced in 2016 by 
the Public Health Minister, Jane Ellison (Department of Health 
and Social Care, 2016). 
There will be major implications for the NHSCSP and workforce 
in the cervical cytology screening laboratories.  The HPV test is 
performed first on a high throughput automated platform and 
the cytology slides are prepared on the HPV positive samples 
meaning there will be fewer slides to screen.  In the 
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observational study where the six pilot sites undertook HPV 
primary screening, the overall HPV positivity rate was found to 
be 12.7%, however in Sheffield the positivity rate was 16% 
(Rebolj et al, 2019).  This means in a workload of 100,000 
samples approximately 13,000 slides will be produced.  On the 
back of the reduction in screening slides and high throughput 
HPV testing platforms, the decision was made to move from 46 
laboratories to larger centres which was originally 10 to 15 or 
4 to 5 based on the options appraisal (Public Health England, 
2017).  The announcement in October 2018 stated there would 
be a maximum of 13 laboratories however in the final 
notification of tender there were a maximum number of nine 
lots (Public Health England, 2018).  As there will be less 
screening centres, this will have an increased impact on the 
cytology workforce and their inability to move to these areas.  
Any woman who is found to have an abnormality from her 
cervical cytology and HPV test is referred to colposcopy for 
further investigation as part of the NHSCSP aims to prevent 
cervical cancer. 
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Figure 4  Protocol for HPV Primary Screening 
  
HR-HPV Test 
HR-HPV -ve HR-HPV +ve 
Cytology triage Routine recall 3y(25-49) 5y(≥50) 
Cytology normal Cytology abnormal – 
borderline or worse 
Re-screen in 1 year 
HR-HPV -ve 
HR-HPV +ve 
Routine recall 
3y(25-49) 5y(≥50) 
Colposcopy referral 
Cytology normal 
Cytology abnormal – 
borderline or worse 
Colposcopy referral Re-screen in 1 year 
HR-HPV -ve 
HR-HPV +ve 
Routine recall 
3y(25-49) 5y(≥50) 
Colposcopy referral 
irrespective of 
cytology findings 
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Colposcopy 
Women are referred for a colposcopic examination if there are 
clinical grounds such as abnormal bleeding including 
postmenopausal bleeding, post-coital bleeding, a suspicious 
looking cervix or through the cervical screening programme 
where they have had an abnormal cervical screening test such 
as high-grade dyskaryosis. 
The colposcope was developed by Hans Hinselmann in 1925 to 
visualise the cervix plus the vagina and vulva utilising optimum 
illumination and magnification (Fusco et al, 2008).  This 
medical procedure is usually performed in an out-patient 
setting.  The woman is examined in the lithotomy position and 
a speculum is inserted in to her vagina (Figure 5).  
 This allows the cervix to be visualised through the colposcope 
and the magnified view enables the colposcopist to identify 
whether there is any cervical abnormality which requires 
treatment or the examination may reveal there is nothing 
wrong.  To help with the examination, dilute acetic acid 
solution and Lugol’s Iodine are applied to the cervix to look for 
characteristic patterns which may indicate pre-cancerous 
changes or cervical cancer (Shafi et al, 2002).  
Acetic acid (3 or 5%) is applied to the cervix with a cotton 
swab and potential abnormal areas turn white, called aceto-
white.  The white area is caused by the acid coagulating with 
cellular proteins indicating higher nuclear density associated 
with precancerous lesions.  Once the acetic acid is applied, the 
aceto-white change is graded 1 to 3 depending on the how 
quickly and the degree of onset of whiteness.  This allows the 
colposcopist to give an opinion as to the grade of possible 
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abnormality i.e. low grade or high grade (Palmer, 2010).  The 
quicker the uptake of acetic acid and the more intense the 
whiteness, the more likely the higher the grade of cervical 
neoplasia.    
Figure 5 Colposcopy Procedure 
 
Image courtesy of Jo’s Cervical Cancer Trust © 
If the colposcopist is unsure they will take cervical biopsies to 
confirm whether there is any abnormality or not.  It is 
estimated that approximately 1% of CIN 1, 5% of CIN 2 and 
more than 12% of CIN 3 will progress to cervical cancer, thus 
high grade CIN is treated as we do not know which lesions will 
progress (Oster, 1993).  If the colposcopist is certain there is 
high-grade present, they may do the treatment there and then 
in the clinic, known as ‘see and treat’ (Dunn et al, 2003: 
Cardenas-Turanzas et al, 2005).  This is usually by means of a 
large loop excision of transformation zone (LLETZ) and in some 
cases they may use ablation techniques such as laser or 
cryotherapy (Prendiville et al, 1989).   
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Cervical cancer can be detected at colposcopy but may be 
recognised without the use of the colposcope.  Features of a 
cervical cancer can be a large friable and ulcerated lesion and 
may bleed when taking a sample.  If a cancer is not obvious, it 
can be recognised by a characteristic mosaic and punctuation 
pattern after the application of acetic acid plus an irregular 
blood vessel pattern referred to as ‘corkscrews’ (Palmer, 
2010). 
The main aim of colposcopy is to detect and treat cervical 
neoplasia which if not treated may develop into cervical 
cancer.  Once HPV is integrated into the cervical epithelium it 
can take years to progress to cervical cancer, however as well 
as progressing, the disease can regress as shown in Figure 6 
(Burd, 2003: Solomon et al, 2002).  
Figure 6 Progression/regression of HPV with cervical 
cancer 
 
 
 
Progression 
Regression 
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Histology 
LLETZ samples are sent to the histopathology department for 
processing and to confirm the successful treatment of cervical 
disease.  As cytology is the microscopic assessment of cells, 
histology is the microscopic assessment of cells within the 
tissue and organ structure.  Histopathology is the microscopic 
assessment of disease of tissue/organ samples and provides a 
critical role in the diagnosis of cancer.  Specimens can include 
anything from skin biopsies – small samples from the skin, 
gross specimens such as the appendix, kidney and amputation 
specimens such as a leg.  Samples can be sent fresh for the 
laboratory to control the fixation of samples or in pots with 
formalin.  Formalin is comprised of 10% formaldehyde with 
buffers and water known as 10% neutral buffered formalin 
(NBF) (Bancroft, 2019).  10% NBF preserves the structure of 
the tissue and cells and also hardens the tissue for further 
processing by cross-linking proteins.   
Specimens are given a unique number on receipt in the 
histology laboratory which is linked to the patient that the 
sample came from.  Specimens can be processed whole or in 
the case of LLETZ specimens, they will be dissected and placed 
in cassettes for processing with their unique number for 
identification.  Samples from the specimen are processed by 
removing water using ascending grades of alcohol, into a 
clearing agent usually xylene which is miscible with both 
alcohol and wax.  This is usually done overnight and when 
finished the tissue samples are embedded in a wax block which 
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supports the tissue when it is cut with a microtome.  Thin 
slices of tissue are cut called sections which are 4 micrometres 
thick, floated on a water bath and picked up with a glass 
microscope slide.  When the section has dried on to the slide 
labelled with the unique number, it is ready for staining.  The 
section is rehydrated going through xylene and descending 
grades of alcohol back to water.  The routine stain in the 
histology laboratory is haematoxylin and eosin (H&E) as it is 
easy to use, automate and is an overall good stain for general 
tissue structures (Bancroft, 2019). The stained slide is looked 
at down the microscope and is usually examined by a 
Histopathologist to interpret the cell structures and give a 
diagnosis. 
Cervical Samples from Colposcopy 
There are mainly two types of samples that are received from 
colposcopy to be diagnosed by the Histopathologist as part of 
the NHSCSP.  A cervical biopsy is a procedure that is done at 
colposcopy and is an out-patients procedure.  When the 
colposcopist examines the cervix and identifies an area which 
may be potentially abnormal, they will remove a small sample 
of tissue for histological examination – the cervical biopsy.  
The colposcopist will have formed their opinion as to the grade 
of abnormality; however the histopathology report will give the 
correct grade of abnormality if it is present.  This is a 
diagnostic sample to confirm if there is the presence of 
precancerous cervical disease or not and whether the patient 
needs treatment or not.  The most popular form of treatment 
is the large loop excision of the transformation zone (LLETZ).   
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LLETZ is the treatment of choice to treat women with high-
grade disease such as CIN 2 or CIN 3 plus cervical glandular 
intraepithelial neoplasia (CGIN). This procedure is usually done 
in an out-patients’ setting as it is easy to perform, inexpensive 
and quick (Prendiville et al, 1989: Martin-Hirsch et al, 2002).  
Local anaesthetic is applied to the cervix and an electrified hot 
wire loop is passed through the cervix incorporating the 
transformation zone to remove the whole area of disease.  The 
loop cuts the tissue but also cauterises the blood vessels 
minimising bleeding.  A piece of cervical tissue is obtained 
which is sent for histological examination to assess any 
cervical disease present, check there is no cancer present and 
if the margins are clear of disease. 
Figure 7  Fresh LLETZ specimen  
 
 
Colposcopy Multi-disciplinary Team Meetings (MDTs) 
Colposcopy MDTs are held between representatives from 
cytology, histology and colposcopy plus the cervical screening 
provider lead (CSPL) who oversees the quality and 
performance of the cervical screening programme in each 
Trust.  They meet to discuss any cases where there are 
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discrepancies and mismatches between any of the findings e.g. 
high grade dyskaryosis on cervical cytology but the histology 
shows CIN 1.  All the slides and histories are reviewed to see if 
the original diagnosis is still valid in view of further clinical 
information.  The team discuss the reviews and agree on a 
suitable management regime for each of these patients.  Other 
cases that are discussed are women who are being managed 
conservatively or women with CGIN to ensure that they have 
appropriate follow up.  These meetings must be held at least 
once a month with all colposcopists attending at least 50% of 
them (Public Health England, 2016). 
Cervical intraepithelial neoplasia (CIN) 
The features to identify abnormalities on cervical cytology are 
very similar to those found to diagnose CIN on histology 
preparations (NHS Cervical Screening Programme, 2012).  The 
NHSCSP uses a three tier system of reporting CIN which 
correlates with the three tier reporting of cervical cytology and 
reflecting that the development of cervical intraepithelial 
neoplasia as a continuous process – see Figure 8.  This is 
opposed to the Bethesda System which is a two tiered system 
of reporting – low and high intraepithelial lesions (Nayar and 
Wilbur, 2014)   
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Figure 8  Progression of CIN to cervical cancer 
 
 
Image courtesy of Cancer Research UK (2019) 
 
Nuclear abnormalities are key features for the diagnosis of 
dyskaryosis in cytology and CIN in histology.  Both histology 
and cytology abnormalities of the cervix share similar 
characteristics for microscopic diagnosis.  Assessment is made 
on the nuclear atypia such as the irregularity in size, clumping 
of chromatin and the nuclear to cytoplasmic ratio.  The more 
pronounced these changes the higher the grade of severity.  
Mitotic activity is an indication of cell activity and possible 
development of cervical abnormality.  These features are seen 
in the epithelium of the cervix which helps with the diagnosis 
of CIN whereas in cytology you have to interpret the variation 
within the cell groups and individual cells to determine the 
Page | 31 
 
degree of dyskaryosis (NHS Cervical Screening Programme, 
2012). 
 
There are three grades of CIN that affect the squamous 
epithelium of the ectocervix (see Figure 2) before the lesion 
develops in to a cancer.  The recognition of CIN is subjective 
and is diagnosed based on characteristic features and patterns.  
The grading of CIN is based upon the depth of epithelium that 
is affected by undifferentiated neoplastic (abnormal) cells, 
where in the epithelium mitotic figures are identified and 
whether the mitotic figures are abnormal or not (Institute of 
Biomedical Science, 2011).   
 
CIN 1 affects the bottom third of the epithelium where the 
cells display nuclear atypia but mature normally through the 
rest of the squamous epithelium.  It is rare to see any mitotic 
activity and these changes are usually associated with HPV.  
CIN 1 will often regress back to normal epithelium, however in 
some cases it will progress to CIN 2.   
 
CIN 2 is diagnosed when there is an increased nuclear atypia 
and is seen up to the middle third of the squamous epithelium.  
CIN 2 may regress hence the colposcopists may manage the 
patient conservatively depending on her circumstances and 
age e.g. she may want to conceive and treatment may affect 
her ability to do so.  By managing conservatively, this allows 
the colposcopist time to see if the disease progresses or not, 
helping to make the judgement as to whether treatment is 
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appropriate (Prendiville, 2009).  The final third of epithelium 
matures normally.  Mitotic figures may be seen in the lower 
two thirds of the epithelium and there may be abnormal 
mitotic figures through these layers.   
 
CIN 3 is the last classification of disease before cancer is 
diagnosed and the nuclear atypia is seen through the full 
thickness of squamous epithelium.  There is more severe 
nuclear atypia associated with CIN 3 and abnormal mitotic 
figures throughout the epithelium.   
 
Cervical glandular intraepithelial neoplasia (CGIN) is the 
precancer of the glandular epithelium of the cervix seen in 
Figure 2 as the endocervix.  CGIN features nuclear atypia 
which forms multilayers in the single layer of glandular 
epithelium called pseudostratification.   
 
Cancer is diagnosed if the abnormal cells have broken through 
the basement membrane of the squamous epithelium and 
invaded in to stromal tissue below.  The stages of cervical 
cancer are classified by the International Federation of 
Gynaecology and Obstetrics (FIGO) (Bhatla et al, 2019).    
 
Margins 
The detection of cervical disease at the margins may be an 
indicator of treatment failure with a possible recurrence and 
may suggest that the woman needs further treatment 
(Manchanda et al, 2008).  There are three margins present on 
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a LLETZ specimen – ectocervical, endocervical and deep lateral 
margin which are illustrated in Figure 9.  Recurrence is higher 
with women who have high grade disease and if it is found at 
the deep lateral margins and/or endocervical margins (al-
Nafussi and Hughes, 1994).  In Arbyn’s met-analysis of 
incomplete excision of cervical precancer as a predictor for 
treatment failure, it was found that overall there were 23.1% 
of women (total women 44,446) that presented with positive 
margins with the overall risk of residual or recurrent disease 
found to be 6.6%.  These are not insignificant numbers/risk 
and require follow up (Arbyn et al, 2017).    
 
It is important that the person reporting the LLETZ is able to 
identify the margins and report whether these are involved 
with cervical disease or not.  There will be some clearance as 
the treated area of the cervix has undergone destructive 
treatment with diathermy and many colposcopists go over this 
area with a diathermy ball.  The recommendation is to paint 
the margins of the LLETZ with different coloured inks to help 
the identification of these when examining the sections down 
the microscope (NHS Cervical Screening Programme, 2012).  
 
HPV 
HPV with associated koilocytes is reported histologically even 
though it is a benign condition and is included as part of the 
RCPath minimum data set.  This is because the cytological 
findings of borderline or low grade dyskaryosis may be 
explained by the presence of HPV (koilocytes) in histological 
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sections from cervical biopsies/LLETZ classified as mismatches 
at the Colposcopy MDTs.  Histological features of HPV 
(koilocytes) are identified by cells with nuclei having a 
‘wrinkled’ outline with slight enlargement but a regular 
chromatin pattern.  The cytoplasm of these cells is vacuolated 
with a clear hard rim around the edge. Koilocytes are mostly 
found in the upper superficial layers of the epithelium.  If any 
koilocytosis is found associated with CIN, the CIN must be 
graded and reported as defined in the NHSCSP guidelines 
(NHS Cervical Screening Programme, 2012). 
 
Figure 9   Diagram to illustrate the margins of a LLETZ 
specimen 
 
 
 
 
Modified image courtesy of efccolposcopy.eu 
  
  Endocervical margin 
Deep lateral margin 
Deep lateral 
margin 
  Ectocervical margin 
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Introduction of Histopathology Reporting by Biomedical 
Scientists 
During the time this study was being written up, RCPath and 
IBMS have issued a joint statement regarding the development 
of BMS reporting histopathology.  A working party from the 
RCPath and IBMS began the discussions in 2010 and the first 
BMS entered the histopathology reporting pilot in 2012 (Horne 
et al, 2018).  This development has followed on from the 
success of BMS reporting abnormal cervical cytology and 
ophthalmic pathology and is a natural progression for BMS 
delivering specimen dissection. This role has also been 
developed due to a chronic shortage of Histopathologists in the 
UK and in order for this to succeed, the barriers concerning 
traditional roles between BMS and Histopathologists need to be 
broken down.  There has been a reluctance of many 
Consultant Histopathologists to accept that non-medically 
qualified scientists can report histopathology if they have had 
the appropriate training and are deemed competent (Liebmann 
et al, 2015).  I have also found resistance to change within my 
own Trust and it is mainly the ‘traditional’ pathologists that are 
reluctant to support any training or change of roles.   
The areas of histopathology that were chosen as part of the 
initial pilot were gastrointestinal and gynaecological pathology.  
This was on the basis that these areas represent high 
workloads with a low risk of litigation, lower complexity and 
contribute to backlogs within departments (Liebmann et al, 
2015).  To be eligible for training in gynaecological pathology 
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reporting, the biomedical scientist must be registered with 
HCPC, be a Fellow (FIBMS) or Member (MIBMS) of the IBMS 
and have at least seven years post-registration experience in 
cellular pathology, although this has recently been reviewed 
and put down to 5 years (IBMS and RCPath, 2017). The BMS 
must have the support of their Trust and the Medical Head of 
Department with a suitably qualified named pathologist to be 
the workplace based supervisor.  In order to be accepted on 
the training programme, any prospective candidate has to 
attend for an interview with a panel of members from the 
RCPath and IBMS.   
The curriculum mirrors the curriculum that is presented to 
histopathology trainees in their first year.  It is an extensive 
programme covering the dissection and reporting of the female 
genital tract.  The training programme is in four stages and is 
expected to take a minimum of four years.  There is a general 
expectation that the BMS will do this training above and 
beyond their normal working duties which is very different 
from what is expected from the trainee pathologists.  Trainee 
pathologists are supernumerary with dedicated time to train 
and study in their workplace.  As most BMS are already very 
busy with their own day to day roles making time to study has 
proved extremely difficult for them to achieve and they have 
had to commit to working weekends and after work to keep up 
with the training programme.  This was confirmed in a 
questionnaire that RCPath and IBMS undertook in 2017 as 
there has been quite a high dropout rate (Nation, 2017).  As a 
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result of these findings, the conjoint board is recommending 
that departments should allow the BMS some protected time 
for their training. 
Advanced Specialist Diploma (ASD) Histopathology 
Training Programme 
 
The first year (Stage A of the curriculum) introduces the BMS 
to histopathology with the focus on gynaecological pathology.  
They are expected to be competent in the cut up of simple 
specimens such as LLETZ plus larger simple specimens such as 
benign hysterectomy samples.  They must be able to 
demonstrate that they can write up reports for appropriate 
histopathology specimens and are able to manage their time.  
To successfully complete their training and move on to Stage 
B, they have to submit a portfolio and pass an exit 
examination.  The portfolio must include evidence of reporting 
a minimum of 750 cases, audits and an interesting case 
report.  There will also be evidence of at least 18 assessments 
in the workplace and regular feedback from the supervisory 
pathologist.  The portfolio is assessed at the end of the year 
and if they pass the examination, they can move on to the 
next stage. 
 
The next stages B and C follow on from stage A and introduces 
the BMS to more complex cases and gynaecological cancers.  
They must report a minimum of a 1000 cases and demonstrate 
their progress reporting more complex cases in their portfolio 
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which is submitted at the end of the year.  The BMS passes 
onto stage C if their portfolio assessment passes strict criteria 
as there is no formal examination at the end of this year.  
Stage C continues the theme of reporting more complex cases 
and includes an exit examination including practical tests such 
as dissecting specimens and reporting cases.  After successful 
completion of stage C and passing the exit examination the 
BMS will be awarded with the RCPath/IBMS Advanced 
Specialist Diploma in Histopathology Reporting (Gynaecological 
pathology).    
 
The final part of training is stage D which is a consolidation of 
all the knowledge and skills that have been learnt through the 
previous stages and prepares the BMS for independent 
reporting.  The supervising pathologist develops a reporting 
plan to aid the BMS to become an independent practitioner.  
Once appointed to the role of histopathology reporting, the 
BMS will work with medically qualified consultants as part of 
the reporting team covering all the roles they do such as 
dissection, reporting and presenting cases at multidisciplinary 
meetings.  They will perform audits, train junior staff and 
participate in appropriate external quality assurance schemes 
(IBMS and RCPath, 2017).  
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Pilot study of Consultant BMS reporting large loop 
excision biopsies of the cervical transformation zone 
(LLETZ) 
As described earlier, Consultant BMS who report cervical 
cytology are highly skilled in the interpretation of cellular 
morphology with an extensive knowledge of the cervix (Smith, 
2009).  In Sheffield, it was realised that there was a potential 
to utilise these skills to the benefit of the Histopathology 
department allowing the Histopathologists to concentrate on 
the more complex gynaecological cases.   
 
LLETZ samples were chosen for this pilot study as they form a 
big proportion of the routine workload for a Gynae 
Histopathologist with plenty of material to interpret.  In the 
majority of cases in Sheffield, a woman is treated with a LLETZ 
if her preceding cervical biopsy showed CIN 2 or above, 
although the ‘see and treat’ policy is gaining favour as it can 
be done in one visit to colposcopy being better for the patient 
and more cost-effective (Dunn et, 2003).  As in the majority of 
cases, there is a preliminary diagnosis made from a previous 
cervical biopsy, hence LLETZ samples are seen as clinically low 
risk and is the method of treatment after the diagnosis of high 
grade CIN/CGIN. 
 
For the clinician, the report generated by the Histopathologist 
should address the following issues (NHS Cervical Screening 
Programme, 2012). 
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 What is the grade of CIN - does it correlate with the 
biopsy if taken plus the colposcopic and cytology findings   
 Is there any evidence of invasion suggesting a possible 
cancer? 
 Are the margins clear as if not may suggest further 
excisional treatment may be required?  
 
The reporter needs to take into account the size and the 
volume of the high-grade lesion plus involvement of the 
disease into the crypts as this may be suggestive of a possible 
risk of invasive cervical cancer (al-Nafussi and Hughes, 1994: 
Ostör, 1993 and Tidbury et al, 1992) 
 
Original Pilot Study of LLETZ Reporting by Consultant 
BMS in Sheffield 
In the original pilot study, two Consultant BMS ‘shadow 
reported’ LLETZ specimens.  This involved my colleague and 
me reporting the LLETZ specimens in ‘real time’ before they 
were finally reported by Dr Branko Perunovic (BP), Consultant 
Histopathologist.  104 LLETZ specimens were assessed and 
according to standard local practice, they had a previous 
diagnosis of CIN confirmed by cervical punch biopsy prior to 
the procedure.  Each specimen was cut in 3mm parallel slices 
and each slice was embedded in a separate block which was 
sectioned at three levels at 80-100µm intervals.  All the cases 
were reported by BP with his conclusions used as the ‘gold 
standard’ for comparison. 
Page | 41 
 
Table 2  Final diagnoses in 104 cases of LLETZ biopsies 
Three tier 
system 
No % Two-tier system No % 
Negative 9 8.7 Negative 9 8.7 
HPV only 11 10.6 
LSIL 14 13.5 
CIN1 3  2.9 
CIN2 14 13.5 
HSIL 76 73.1 
CIN3 62 59.6 
High-grade 
CGIN 
2 1.9 AIS 2 1.9 
Invasive 
carcinoma 
3 2.9 
Invasive 
carcinoma 
3 2.9 
 
The 104 cases as seen in Table 2 were independently 
examined by the two Consultant BMS (KE, ND) and our 
diagnosis was based only on our previous knowledge and 
experience. Although we were both experienced cytologists, 
one of us had practically no experience in interpreting 
histology, whilst the other had gained a limited experience in 
interpreting histology prior to this study by participation in 
preparation for multidisciplinary team meetings and research.  
We used pro-forma reports compliant with the RCPath 
minimum data set, thus the comments were restricted to 
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stating the presence or absence of all of the following 
histological findings: 
• Cervical Intraepithelial Neoplasia (CIN) – 1-3 
• Cervical Glandular Intraepithelial Neoplasia (CGIN) 
• Histological hallmarks of HPV infection (e.g. koilocytosis) 
• Invasive neoplasia 
• Status of the ectocervical, endocervical and deep lateral 
margins of excision. 
 
The results from the Consultant BMS reports were compared to 
those in the final report and the inter-observer variations for 
grading of CIN were calculated using kappa () test. This 
evaluation also included assessment of the inter-observer 
correlation in regards to two-tier system for grading of 
Squamous Intraepithelial Lesions (SIL), with HSIL comprising 
lesions designated as CIN 2 and CIN 3 in the three-tier 
system, whilst the diagnosis of LSIL included CIN 1 and lesions 
showing evidence of HPV infection only (e.g. koilocytosis) (Ellis 
et al, 2012).  For Consultant BMS 1 the inter-observer 
agreement for each report of negative, CIN 1, CIN 2 and CIN 3 
was 85.9% with  = 0.742 and Consultant BMS 2 had inter-
observer agreement of 81.8% with  = 0.674.  The inter-
observer agreement of negative, low grade SIL and high grade 
SIL was 92.9% with  = 0.812 for Consultant BMS 1 and for 
Consultant BMS 2 was 86.9% with  = 0.658.  The kappa 
degree of agreement is explained in Table 5.  For the 
Consultant BMS their inter-observer agreement was classified 
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as good with Consultant BMS 1 achieving very good agreement 
for the SIL correlation.   
 
When the correlation was assessed for the interpretation of 
margin involvement, there was more of a difference between 
the Consultant BMS.  Consultant BMS 1 had an excellent 
agreement with the Histopathologist regarding the 
endocervical, ectocervical and deep lateral margins of excision 
( = 0.942, 0.864 and 1.0 respectively).  Consultant BMS 2 
showed a much lower level of agreement with ( = 0.635, 
0.561 and 0.013 respectively).  I concluded that the difference 
was due to previous experience in a histopathology laboratory 
and I recognised LLETZ samples as 3-dimensional specimens 
being able to recognise margins. 
 
Histological evidence of HPV infection was assessed.  There 
was found to be very good inter-observer agreement between 
the Histopathologist and Consultant BMS 1 with a  agreement 
of 0.946 and with Consultant BMS 2 this was only fair at a  
agreement of 0.301. 
      
As there was good correlation between the Consultant BMS 
and the final reports issued by the Histopathologist, I decided 
to expand the remit of the pilot study.  The plan was to recruit 
more Consultant BMS from the UK and to see whether these 
promising results could be replicated wider.  If a Consultant 
BMS was allowed to report LLETZ within the confines of the 
NHSCSP, this would allow Consultant Histopathologists to 
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concentrate on the more complex and cancer gynaecological 
specimens providing a more timely and cost-effective service 
for  women and the NHS.   
As this study has been on-going the conjoint board of the 
IBMS and RCPath have introduced the ASD in Histopathology 
Reporting in Gynaecological Pathology/ Gastrointestinal Tract 
(GIT) Pathology.  The training programme associated with the 
ASD in Histopathology Reporting takes a minimum of four 
years.  This ASD will be reviewed in line with my proposal of 
reporting restrictions to LLETZ specimens only instead of all 
gynaecological samples.  This will be a module specific to 
LLETZ specimens as opposed to the full curriculum for 
gynaecological pathology.  
 
 
 
 
 
 
  
Page | 45 
 
Methods 
Recruitment of Volunteers 
As stated earlier, the original pilot showed very promising 
results but only involved two Consultant BMS.  To continue the 
development of this work, I applied to the Trust’s NHS 
Research Ethics Committee (REC) and was granted permission 
to continue the work – the study was registered as ‘STH14976 
ABMSP LLETZ Reporting’. 
The data from the original pilot of myself and my colleague 
was presented at the IBMS Congress in 2009 (Appendix A) and 
the International Academy of Cytology (IAC) scientific meeting 
in Edinburgh 2010.  As part of the presentation at the IBMS 
Congress and through the Consultant BMS network, volunteers 
were asked to come forward to extend the study to include 
more Consultant BMS within the UK.  Once I got approval, Dr 
Branko Perunovic, the Clinical Director for Laboratory Medicine 
and Gynaecological Histopathologist at Sheffield Teaching 
Hospitals was my supervising pathologist for this work.  We 
designed a structure for how the study would work.   
BMS who volunteered ideally should have the ASD in cervical 
cytology however one of the volunteers had extensive 
experience of specimen dissection in histology with a particular 
interest in cervical specimens.  It was important that the BMS 
had microscopy experience and knowledge of cervical disease 
as this would help with their interpretation of the cases.  It 
was paramount that they had the support of a Histopathologist 
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based in their workplace to mentor and guide them through 
the process of reporting.  As part of the recruitment process 
and if feasible, Dr Perunovic and I visited the volunteer BMS 
together with their pathologist mentors to explain how the 
study would be managed and what was expected of them.  
Volunteers were expected to undertake the reporting in their 
own time and there was no funding associated with this study.   
Nine Consultant BMS volunteered to take part in this study 
which included me plus one senior BMS who was not a 
cytologist but as stated earlier, had vast experience in 
histopathology and the dissection of specimens. Four of the 
Consultant BMS had a background that included previous 
experience of working in a histology laboratory and five had a 
purely cervical cytology background however they were 
exposed to reviews of LLETZ samples at Colposcopy MDTS.  Of 
the original nine, only six Consultant BMS managed to 
complete the full set of slides.  The other three Consultant BMS 
were unable to continue with the study due to work 
commitments and time restraints.  I felt that there was not 
enough data from them to contribute to the overall results for 
the study as they had only completed between six to 30 cases.  
The BMS with dissection experience had to decline to take part 
too, due to time commitments and personal reasons.  A 
training day was arranged for the interested BMS so that they 
could get an idea of what was expected of them. 
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Training Day 
The training day was held approximately a month before the 
proposed start date led by Dr Branko Perunovic who was the 
overall supervising pathologist and my workplace mentor 
based at the Royal Hallamshire Hospital, Sheffield.  The 
training programme (Figure 10) gave an overview of how the 
pilot was to operate and included a video of how LLETZ 
specimens arrived in the histopathology laboratory.  The video 
demonstrated how the LLETZ specimens were measured and 
dissected to obtain histological slides to examine under the 
microscope.  The video was important to explain to the 
Consultant BMS how sections of the LLETZ were orientated in 
the blocks and how the margins presented.  If any 
premalignant disease is present at the margins, there is the 
possibility that the lesion may not have been fully excised and 
a repeat procedure may be required.  
The next part of the training programme was a multi headed 
microscope session with examples of normal histology of the 
cervix, the premalignant phases of cervical cancer called CIN 
and CGIN, invasive cervical cancers and finally difficult to 
interpret benign conditions such as microglandular hyperplasia 
versus premalignancy of the cervix (NHS Cervical Screening 
Programme, 2012).  This session also covered slides where the 
section had been cross-cut and where there was diathermy 
artefact at the margins of the LLETZ which may cause the 
Consultant BMS problems in interpretation.  The final stage 
was a self-assessment session where individuals were given a 
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set of slides with various stages of cervical disease - benign, 
premalignant and cancer for them to give a histological 
diagnosis and was followed up by a multi-header microscope 
session to review these cases.  
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Figure 10 Training Programme for Consultant BMS  
 
 
 
 
 
PROGRAMME FOR SHADOW REPORTING OF LLETZ 
SPECIMENS TRAINING DAY FOR ADVANCED BIOMEDICAL 
SCIENTIST PRACTITIONERS (ABMSPs) 
 
 
9.30 am   Coffee  
   
10.00 am Introduction 
To include background, format and protocol 
KE 
   
10.20 am Training session 
 
Multiheaded discussion of basic problem areas 
 
Wart virus v ‘look-a-likies’ 
Atrophy and thin epithelium 
Reactive metaplasia/repair 
Early stromal invasion v CIN in crypts 
Grading – ‘stripped’ epithelium 
- problems of cross cutting 
- equivocal CIN 
 
CGIN v TEM 
Microglandular hyperplasia 
Invasion v CGIN 
 
Margins 
Orientation 
BP 
   
12 noon Lunch  
   
12.45 pm Self-assessment section  
   
1.30 pm Review  
   
2.15 pm Reporting of cases  
   
3.00 pm Close  
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Selection of LLETZ Specimens 
157 consecutive LLETZ samples from the Histopathology 
Department, Royal Hallamshire Hospital, Sheffield were used 
for this study.  The number selected was based on the 
estimation that a trainee pathologist in Sheffield would look at 
150 LLETZ specimens during their training period of general 
pathology of four years which would include gynaecological 
pathology.   157 cases were prepared for the study as detailed 
below and there would still be a minimum of 150 cases to 
compare in the event of any slides being broken or lost in 
transit. 
Preparation of Slides from LLETZ Specimens 
Each LLETZ specimen was sent to the histopathology 
laboratory at the Royal Hallamshire Hospital in Sheffield in a 
container with no fixative.  Each LLETZ specimen was 
measured and photographed with a ruler to gauge the size of 
the specimen before it was placed in 10% buffered saline 
formalin for 24 hours to fix in preparation for dissection (Figure 
11).  Any separate specimens that were received in the same 
container were also noted on the request form, measured and 
fixed too. 
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Figure 11 Fresh LLETZ specimen  
 
After 24 hours of fixation with 10% formalin, the LLETZ sample 
was dissected and cut into sequential 3mm parallel slices as 
outlined in NHSCSP guidance (NHS Cervical Screening 
Programme, 2012).  Each slice of the LLETZ was placed with 
the cut surface, face down in to the appropriately labelled 
cassette, however the last block was reversed so that block 
had its cut surface face down, known as  ‘bookending’.  For 
example with Figure 12, A to D were embedded face down and 
the final block E was turned the other way so that it’s cut 
surface was face down.  
Each slice was embedded into a separate cassette to create a 
wax block labelled with its unique histology number.  It is 
important that the final reporter understands how the 
specimen had been sliced and arranged in cassettes so that 
they could identify the margins on examination down the 
microscope.  If there was concern that there was disease in 
the end block such as E in Figure 12, the block could be melted 
down and embedded the other way up.   
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Figure 12 Fixed LLETZ specimen dissected and labelled  
 
Each LLETZ sample was processed to wax overnight on the 
Sakura VIP 5, one of the automated tissue processors on the 
following schedule (Table 3). 
Table 3 Routine processing schedule on Sakura VIP 5 
Reagent Time Vacuum/Pressure Temperature Agitation 
Formalin 0 On Ambient Fast 
70% IDA 30mins On Ambient Fast 
95% IDA 30mins On Ambient Fast 
99% IDA 30mins On Ambient Fast 
99% IDA 1hr On Ambient Fast 
99% IDA 1hr On Ambient Fast 
99% IDA 1hr On Ambient Fast 
Xylene 1hr  On Ambient Fast 
Xylene 1hr 
15mins 
On Ambient Fast 
Xylene 1hr 
15mins 
On Ambient Fast 
Paraffin 
Wax 
1hr  On 60oC Fast 
Paraffin 
Wax 
1hr 
15mins 
On 60oC Fast 
Paraffin 
Wax 
1hr 
15mins 
On 60oC Fast 
Paraffin 
Wax 
1hr 
15mins 
On 60oC Fast 
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The tissue goes through a series of graded alcohols, xylene 
and finally paraffin wax.  The graded alcohols get more 
concentrated as they remove water from the tissue and xylene 
is classed as a ‘clearing’ agent as it is miscible with both 
alcohol and wax.  Xylene replaces the alcohol in the tissue 
before it is replaced with molten wax.  The wax impregnated 
tissue is embedded into a bigger block of molten wax which 
gives the tissue stability and rigidity to allow the tissue to be 
sectioned without damage or distortion (Orchard and Nation, 
2011: Bancroft and Gamble, 2007). 
Each block from the LLETZ sample was trimmed on a 
microtome so that there was a full face of tissue.  The blocks 
were kept cool on ice which makes them easier to cut and 
reduces artefact such as shattering marks which may affect 
the microscopic interpretation.  Once the full face was 
established, a section was taken at 4µm and floated on a 
water bath just below the melting point of the wax to enable 
the section to flatten out.  The best section was picked up on a 
glass microscope slide with that case’s unique laboratory 
number and for the purposes of this study, the next section in 
the ribbon was taken known as a serial section.  As the study 
section was taken from the same ribbon as the original 
reported section, they are virtually identical.  The block was 
trimmed for a further 80-100µm intervals and the 
aforementioned cutting and selection procedure was repeated.  
This meant that for each block, there were three sections and 
a serial section from the same ribbon was taken at the same 
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time.  Using Figure 2 as an example, it would mean that there 
were five sections (A to E) with levels 1 to 3 that were 
replicated for the serial sections for this study.  This means 
that there would be 15 sections on this particular case to be 
examined under the microscope. 
Each section was dried and stained with Haematoxylin and 
Eosin (H&E) on the Thermo Shandon Linistain. The dyes are 
water based and will not mix with the wax impregnated tissue.  
The slides undergo a reversal of the processing schedule in 
order to take the tissue back to water using xylene and graded 
alcohols.  Haematoxylin stains the nucleus blue in the tissue 
and eosin stains the cytoplasm various stages of red.  Each 
slide was mounted using the Sakura Tissue-Tek Film 
Coverslipper to produce a permanent slide for microscopy 
assessment. 
Patient Confidentiality 
Each LLETZ specimen for the purpose of this study was given a 
number starting from one so that patient anonymity would 
remain.  This number was cross-referenced to the original 
unique histology number so that the clinical details and history 
could be transferred to the study request form and then be 
traced back to the final diagnostic report to compare the 
reports issued by the Consultant BMS to the report generated 
by the Consultant pathologist. 
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Study Request Form 
The study request form was based on the information from the 
original request form but all patient identifiable data was 
removed to maintain patient confidentiality.  The study request 
form included the patient’s age, cervical screening history, 
previous histology and a photograph of the LLETZ specimen 
with the size of the specimen and the number of blocks taken.  
A request form was produced for each of the 157 cases with all 
the details transferred from the original request form and 
followed the guidelines as set down by the NHSCSP as shown 
below in Figure 13.  Each of the forms was laminated to ensure 
that they were robust enough to withstand the handling of 
postage and packaging around the country. 
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Figure 13 Request Form 
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Proforma Report Form 
A proforma report form (Figure 14 and Figure 15) was 
designed for the Consultant BMS to use as a report template 
based on the RCPath and NHSCSP minimum dataset with tick 
boxes to enable easier statistical analysis (NHS Cervical 
Screening Programme, 2012).    
Each of the reporting categories on the proforma were cross-
referenced to numbered codes that represented all the 
different disease reporting categories as seen in Table 4 based 
on the guidelines for Histopathology reporting in the NHSCSP 
(NHS Cervical Screening Programme, 2012).  In Table 4, 
numbers have been assigned to reporting profiles where there 
may be dual pathology in the LLETZ such as CIN and CGIN – 
classified as 10.  This should allow for every combination of 
cervical disease and aid correlation when the results were 
collated.  This table was also extended to include whether the 
reporting category should be assessed as low or high grade 
disease of the cervix to help with analysis of results.   
The design of the proforma report form also allowed for 
statistical analysis based on The Bethesda System of reporting 
using their terminology of low grade squamous intraepithelial 
lesion (LSIL) and high grade squamous intraepithelial lesion 
(HSIL) (Koss and Melamed, 2006).  The proforma included 
whether premalignant cervical disease was present (CIN), the 
grade if applicable, evidence of HPV infection and whether 
there was any disease present at the margins.  There was 
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space for further tests to be requested such as more levels 
from the histology blocks and extra stains such as 
immunocytochemistry to help in the diagnosis, if needed but 
they would not be undertaken routinely.   
Many Histopathologists use P16INK4a (p16) for difficult cases to 
help identify whether equivocal CIN is high grade or low grade 
for the final diagnosis (Liu et al, 2017).  Examples of other 
diagnostic conundrums include differentiation between florid 
metaplasia and CIN 3 with a positive test indicating the lesion 
is premalignant (Tsoumpou et al, 2009: Cuschieri and 
Wentzensen, 2008).   
On the reverse of the proforma, there was space for any 
comments that the Consultant BMS may wish to put against 
each block number if they have had any difficulties in 
differentiating between premalignant cervical disease and 
benign mimics.  The Consultant BMS reports were compared to 
the final histology reports issued by one of four Consultant 
Histopathologists that report gynaecological specimens at the 
Royal Hallamshire Hospital part of Sheffield Teaching Hospitals 
NHS Foundation Trust (STHFT).   
At STHFT, all the Histopathologists are specialised into 
different disciplines such as gynaecology, skin, renal etc. and 
report these cases only.  At district general hospitals, the 
Histopathologists are general pathologists and report on all 
cases that come through their department.  The four Gynae 
Histopathologists at STHFT have at least 10 to 30 years of 
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experience specialising in Gynae pathology and have worked 
together for a long time sharing slides between them for 
second opinions hence their reporting is remarkably consistent.  
During my time working with them reviewing their cases at the 
Colposcopy MDT, there have been very few occasions where 
there have been any differences of opinion.  This has been 
further corroborated by my role as cervical screening provider 
lead (CSPL) where I have to audit the history of women who 
have developed cervical cancer and part of this includes the 
review of histology.  Again it was extremely rare that there 
were any changes of opinion between the STHFT Gynae 
Histopathologists.    
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Figure 14 Proforma Reporting Form for Consultant BMS 
– front page 
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Figure 15 Proforma for Consultant BMS Reports – back 
page 
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Table 4 Numbers used to identify different disease 
classification 
Proforma 
Report Number 
Disease representation Cervical disease 
classification  
0 No CIN No disease 
1 CIN 1 Low grade 
2 CIN 2 High grade 
3 CIN 3 High grade 
4 Ungradeable CIN High grade 
5 Equivocal CIN High grade 
6 Equivocal CGIN High grade 
7 Probably low grade CIN Low grade 
8 Probably high grade CIN High grade 
9 Cervical glandular 
intraepithelial neoplasia 
(CGIN) 
High grade 
10 High grade CIN/CGIN High grade 
11 Squamous carcinoma of 
cervix (SCC) 
High grade 
12 Stratified mucin-producing 
intraepithelial lesion 
(SMILE)  
High grade 
13 Low grade CIN/CGIN High grade 
There are many reporting grades that are adopted to follow 
the terminology as set out in the NHSCSP Histopathology 
Reporting guidance.  The reporting style should be clear and 
concise so that the clinician can interpret the report in order to 
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manage the patient and any subsequent treatment.  For 
example, a woman diagnosed with CIN 2 may be managed 
conservatively depending on her circumstances – she may be 
offered ablative treatment such as laser, excisional treatment 
e.g. LLETZ or just put on surveillance.   In a clinical setting, 
the reporter would review the slide with a colleague if they 
were unsure of the diagnosis such as a premalignant decision 
versus a cancer or whether there was disease present at the 
margins.  As this was a research project, the Consultant BMS 
had to make their decisions independently and send their 
opinions back to me prior to their results being released.    
To enable the Consultant BMS to get feedback and to complete 
their learning loop, once I had their opinions the results were 
released back to them while they still had the slides so that 
they could review them with their mentor.  Some Consultant 
BMS took digital images of areas of the slides where they had 
difficulty with their diagnosis so that they could discuss with 
me and Dr Perunovic to get feedback as to where they may 
have misinterpreted the case.  To reiterate, the results were 
only disclosed back to the Consultant BMS once I had received 
their opinions electronically or by paper.  When I received their 
results, I entered them on to the central spreadsheet.    
Initial review of slides by primary researcher 
Dr Branko Perunovic kept the master list of original histology 
numbers to compare with the cases in this study.  He provided 
the information for me to set up the request forms and I was 
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the first to look at the slides.  Once I had finished my 
reporting, Dr Perunovic compared my report to the original 
report so that I could fill out the summary table as seen in 
Table 6.  I then collated the final report form as seen in Figure 
16.  I had to be first as I was distributing the slides to the 
other Consultant BMS and giving them the results and 
feedback. 
Reviews by Consultant BMS 
It was expected that the study would take approximately six 
months, however it was delayed due to workload pressures 
within the volunteer group plus the long term sickness of one 
of the BMS, so that it actually took 12 months to complete.  
Slides from the cases I had reported were packed safely and 
securely in slide cases together with their request forms and 
sent to each participant through the post with Royal Mail.  Two 
box slide sets which equated to ten cases at a time were sent 
to each Consultant BMS and these were tracked on a 
spreadsheet which was the central register.  The central 
register tracked the dates of who had which cases, when they 
sent their reports back to me electronically and the date when 
I received the original paper reports together with the cases 
back at base.  By having a central register, I was able to keep 
track of where the slides had been and what cases needed to 
be sent on.   
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Statistical Analysis 
All data sent back from each Consultant BMS was entered on 
to a Microsoft Excel spreadsheet and statistical analysis was 
performed using the kappa test (κ).  The kappa test is used for 
‘determining the agreement between two operators or 
techniques’ (Blann, 2015).  This calculation also takes in to 
account the level of agreement that could occur if left to 
chance.  
κ = Observed agreement – Chance agreement 
Maximum agreement – Chance agreement 
κ = ΡO – ΡE
1 - ΡE
This calculation above represents the ‘chance-corrected 
proportional agreement’ where 
 n = total observed frequency (total number of specimens of
which in this case is 157
 OD = sum of observed frequencies along the diagonal
 ED = sum of expected frequencies along the diagonal
 ΡO = OD/n
 ΡE = ED/n
 1 in the denominator represents maximum agreement
(Watson and Petrie, 2010) 
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Table 5 The kappa statistic 
Value of kappa Strength of agreement 
0 - 2 Poor 
0.21 – 0.4 Fair 
0.41 – 0.6 Moderate 
0.61 – 0.8 Good 
0.81 – 1.0 Very good 
The kappa test will bring a result back of between 0 to 1 
depending on the levels of agreement and disagreement which 
is detailed in the table above with a kappa value of 1 
representing excellent agreement and 0 representing 
agreement left to chance (Altman and Bland, 1994: Blann, 
2015) 
In this study, I was comparing the performance of the 
Consultant BMS against the final report issued by the 
Histopathologists.  The kappa test was applied to the number 
of agreements and disagreements between the Consultant 
BMS and Histopathologists.   
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Figure 16 Shadow Reporting Report Form 
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Results 
The total results were collected and tabulated below compared 
with the with final pathologists report which was set as the 
gold standard.  Each case is labelled 1 to 157 with the final 
report column showing the report as the disease category as 
stated in Table 4 e.g. 3 represents CIN 3.  Each Consultant 
BMS is shown by their initials and the shaded boxes represent 
agreement against the final report.   
Table 6 Histopathology grading on LLETZ samples by 
Consultant BMS 
No 
Final 
Report K A N B M P 
1 3 3 3 3 3 3 3 
2 0 0 1 0 10 7 2 
3 3 3 2 3 3 2 2 
4 2 2 2 2 3 2 2 
5 10 10 10 10 10 10 3 
6 3 3 3 8 3 3 3 
7 0 0 0 0 0 0 1 
8 1 2 2 2 2 1 8 
9 3 3 3 3 3 2 3 
10 0 0 0 0 2 0 0 
11 3 3 8 3 3 3 0 
12 3 3 3 3 3 3 3 
13 3 3 3 3 3 3 3 
14 3 11 3 3 3 3 3 
15 0 0 0 0 0 1 0 
16 3 3 3 3 3 3 2 
17 2 3 2 2 3 2 2 
18 3 3 3 3 3 3 3 
19 2 3 2 3 3 3 3 
20 1 3 1 2 2 2 3 
21 11 11 11 11 0 11 0 
22 1 3 1 1 3 3 3 
23 0 0 0 0 0 0 0 
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24 0 0 1 0 1 7 2 
25 3 3 3 3 3 3 3 
26 3 3 3 3 2 3 3 
27 1 1 0 0 1 1 0 
28 3 3 3 3 3 3 3 
29 3 3 3 3 3 3 3 
30 3 2 2 3 3 2 2 
31 3 3 2 3 3 3 3 
32 0 0 0 0 1 0 1 
33 0 0 1 0 1 1 0 
34 0 1 0 0 3 0 0 
35 3 3 3 3 10 3 3 
36 3 3 3 3 3 3 3 
37 3 3 3 3 3 3 3 
38 2 2 2 2 3 2 8 
39 3 3 3 3 2 3 3 
40 3 8 8 8 3 8 3 
41 0 12 0 0 12 0 0 
42 3 3 3 3 3 3 3 
43 2 2 2 2 3 2 2 
44 2 3 3 3 3 3 3 
45 2 3 2 2 3 2 2 
46 2 2 3 3 3 3 3 
47 2 3 3 1 3 8 1 
48 3 3 3 3 3 3 1 
49 2 0 1 2 2 8 1 
50 3 3 3 3 3 3 3 
51 0 0 0 0 1 0 0 
52 3 3 3 2 3 3 1 
53 3 3 3 3 2 3 3 
54 0 0 0 0 2 0 0 
55 3 3 3 3 11 3 3 
56 2 3 2 2 3 2 2 
57 0 0 0 0 2 7 1 
58 3 3 3 3 3 3 3 
59 3 3 3 3 3 3 3 
60 2 2 1 4 3 8 0 
61 0 0 0 0 13 0 0 
62 0 0 0 0 0 0 8 
63 3 3 3 3 3 3 3 
64 3 0 0 4 8 8 0 
65 3 3 3 3 3 3 2 
66 3 3 3 3 3 3 3 
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67 0 1 1 1 2 1 1  
68 2 2 1 1 2 1 1  
69 3 3 3 3 3 3 2  
70 12 12 12 10 12 0 12  
71 3 0 0 0 1 0 0  
72 0 0 0 0 0 0 0  
73 11 3 3 3 3 3 3  
74 3 3 3 3 3 3 3  
75 2 3 2 3 3 3 1  
76 11 11 3 3 12 3 3  
77 0 8 0 8 3 1 0  
78 3 3 3 3 3 3 3  
79 3 3 3 3 3 3 3  
80 3 2 3 2 3 2 3  
81 0 0 0 0 0 0 0  
82 3 3 3 3 3 3 3  
83 0 0 0 0 0 0 0  
84 3 2 3 3 3 2 1  
85 3 3 3 3 3 3 3  
86 3 3 3 3 2 3 3  
87 3 3 3 3 3 3 3  
88 3 3 3 3 3 3 8  
89 3 3 3 3 3 3 3  
90 0 0 0 0 0 1 0  
91 1 0 0 0 1 0 0  
92 3 3 3 3 3 3 3  
93 3 0 2 3 3 3 3  
94 2 2 1 1 2 1 2  
95 2 1 1 7 2 1 1  
96 2 2 2 7 2 2 0  
97 3 3 3 3 3 3 8  
98 3 3 3 3 3 3 3  
99 3 3 3 3 3 3 3  
100 3 3 2 2 1 1 0  
101 0 0 0 0 1 0 0  
102 3 3 2 3 3 1 0  
103 3 3 3 3 3 3 2  
104 3 3 3 3 3 3 3  
105 3 3 3 3 3 11 3  
106 0 0 0 0 0 0 0  
107 3 3 3 3 3 3 3  
108 1 0 0 0 1 0 0  
109 11 3 3 3 3 3 3  
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110 3 3 3 3 3 3 3  
111 3 2 2 3 3 2 2  
112 3 8 0 8 2 1 0  
113 3 2 1 2 3 1 0  
114 3 1 3 3 3 3 3  
115 2 3 3 3 3 2 2  
116 3 3 3 3 3 2 3  
117 3 3 3 3 3 3 3  
118 3 3 3 3 3 3 3  
119 3 3 3 3 11 3 3  
120 3 3 3 3 3 3 8  
121 3 0 0 0 0 0 0  
122 10 3 10 10 10 10 3  
123 1 7 3 0 1 2 2  
124 0 7 0 0 0 0 2  
125 3 3 2 2 3 8 2  
126 3 3 3 3 3 3 2  
127 3 3 3 3 3 3 3  
128 11 11 3 3 3 11 3  
129 0 0 2 1 3 3 2  
130 2 8 0 0 2 8 2  
131 3 3 2 3 3 3 3  
132 1 1 1 1 3 1 2  
133 3 3 3 3 3 3 3  
134 3 3 3 3 3 3 3  
135 2 2 2 2 2 2 2  
136 3 0 0 3 0 2 0  
137 3 3 3 3 3 3 2  
138 3 8 0 8 3 3 2  
139 3 11 3 3 3 3 3  
140 3 3 3 3 3 3 3  
141 3 3 3 3 3 3 3  
142 3 3 3 3 3 3 3  
143 11 11 11 3 3 3 3  
144 3 3 2 2 3 3 2  
145 3 3 3 3 3 3 3  
146 3 3 3 3 3 3 3  
147 3 3 3 3 3 3 2  
148 3 3 3 3 3 3 3  
149 12 12 12 12 8 3 12  
150 11 11 2 11 3 3 2  
151 3 3 3 3 3 3 3  
152 2 3 3 3 3 3 3  
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153 3 3 3 3 3 3 3 
154 3 3 3 3 3 3 3 
155 3 3 3 1 3 3 3 
156 0 0 0 0 0 0 0 
157 12 12 12 12 12 12 0 
Table 7 Final Histological Outcome of 157 cases 
Grade of Disease Number of Cases Percentage 
No CIN (0) 26 16.6% 
CIN 1 (1) 8 5.1% 
CIN 2 (2) 21 13.4% 
CIN 3 (3) 90 57.3% 
High grade CIN/CGIN (10) 2 1.3% 
Squamous carcinoma of cervix 
(11) 
7 4.5% 
Stratified mucin-producing 
intraepithelial lesion (SMILE) 
(12) 
3 1.9% 
Table 8 Comparison of annual reporting rates in 
England and STHFT (2017/18) 
Grade of disease England %* STH Numbers STH % 
Inadequate 0.2 0 0 
Negative 14.3 56 11.3 
CIN 1 12.1 28 5.6 
CIN 2 24.9 18 3.6 
CIN 3 43.7 336 67.7 
CGIN 2.7 4 0.8 
Cancer 2.0 54 10.9 
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*Please note on the national returns HPV/cervicitis (Source
KC65 Part E, NHS Digital) have been recorded but for this 
purpose they have been included as negative (NHS Digital, 
2018). 
The figures in Table 7 for cervical cancer percentages are lower 
than in Table 8 as they were for 2010/11 rather than 2017/18.  
This can be explained as regional cancer centres were starting 
to be established and would explain the differences between 
the cancer reporting rates for England compared to STHFT in 
Table 8.  There are higher rates at STHFT which I believe are 
due to this site being designated as a regional cancer referral 
centre.  This means that the local general hospitals should 
refer any women with suspected gynaecological cancers to 
their regional specialist centres for surgery, hence their 
histology will be reported on these sites explaining the higher 
rates of cancer that are reported.   
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Table 9  Summary of Reporting Grades 
Code Final K A N B M P 
0 26 29 31 30 14 22 33 
1 8 6 13 8 11 15 12 
2 21 15 23 16 18 19 29 
3 90 88 81 87 101 85 75 
4    2    
5        
6        
7  2  2  3  
8  5 2 5 2 7 6 
9        
10 2 1 2 3 4 2  
11 7 7 2 2 2 3  
12 3 4 3 2 4 1 2 
13     1   
Total 157 157 157 157 157 157 157 
 
Results Analysis 
Looking at the specimens separately before statistically 
analysing them, there was a variation in the reporting as you 
would expect.  There were 26 specimens that were reported as 
having no CIN (O) but the range reported by the Consultant 
BMS was 14 to 33.  There were eight cases reported as CIN 1 
(1 and 7) and the Consultant BMS reporting numbers varied 
from between 8 to 18.  Overall for specimens classified as CIN 
2 (2, 4, 5 and 8) there were 21 reported with the Consultant 
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BMS range from 20 to 35 cases.  There were 95 cases reported 
as high grade CIN and CGIN (3, 9, 10, 12 and 13) with the 
range for the Consultant BMS between 86 to 110 cases.  There 
were seven cancers with the Consultant BMS reporting from 
seven to none of them. 
Two Consultant BMS missed the same cervical cancer case and 
reported it negative.  This case was reported as FIGO stage 
1A1 with a small area of micro-invasion.  It must be noted that 
the previous cervical biopsy was reported as suspicious of 
cervical cancer and the subsequent LLETZ if reported as 
negative would have been checked by another colleague.  This 
would be because there was a significant discrepancy between 
the two reports from the same patient and would not have 
been missed in a ‘real life’ setting.  All other cervical cancers 
were either correctly identified or reported as high grade. 
In Table 9, there is a greater variation of the reporting grades 
from 0 to 13 between the Consultant BMS and the 
Histopathologists.  None of the Histopathologists reported the 
histology as described in Table 4 represented by the numbers 
4, 5, 6, 7 and 8 which covered equivocal, probable or 
ungradeable categories.  I believe this is due to the fact that 
the Histopathologists are very experienced and are used to 
diagnosing specific lesions.  This may have been further helped 
by the Histopathologists using immunocytochemistry such as 
p16 to help identify whether a lesion was high grade CIN or 
not, or requesting further levels to help with their decision 
making.  These extra interventions were not available to the 
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Consultant BMS to grade and may explain why they reported 
more samples as equivocal or probable plus they were far less 
experienced than the Histopathologists. 
In this series of LLETZ samples, there were no samples that 
only had CGIN (9) reported by the Gynae Histopathologists.  
There were two LLETZ that were reported with co-existing 
CGIN and CIN. 
The following tables show initial overall agreement of all the 
positive and negative reports of all the Consultant BMS with 
their initials compared with the final results of the pathologists 
labelled as Path. 
Tables 10 (K, A, N, B, M and P) Total positive and negative 
agreements 
K K - Positive K- Negative Total 
Path - Positive 123 8 131 
Path - Negative 5 21 26 
Total 128 29 157 
Percentage agreement = 91.7%  κ = 0.714 
A A - Positive A - Negative Total 
Path - Positive 121 10 131 
Path - Negative 5 21 26 
Total 126 31 157 
Percentage agreement = 90.4%  κ = 0.679 
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N N - Positive N - Negative Total 
Path - Positive 124 7 131 
Path - Negative 3 23 26 
Total 127 30 157 
Percentage agreement = 93.6%  κ = 0.783 
B B - Positive B - Negative Total 
Path - Positive 128 3 131 
Path - Negative 15 11 26 
Total 143 14 157 
Percentage agreement = 88.5%  κ = 0.491 
M M - Positive M - Negative Total 
Path - Positive 126 5 131 
Path - Negative 9 17 26 
Total 135 22 157 
Percentage agreement = 91.1%  κ = 0.656 
P P - Positive P - Negative Total 
Path - Positive 115 16 131 
Path - Negative 9 17 26 
Total 124 33 157 
Percentage agreement = 84.1%  κ = 0.480 
The overall agreement between the Consultant BMS and the 
final Histopathologist report for negative and positive results 
was classed as very good with the kappa test but this was a 
very simplistic view of overall inter-observer agreement and 
disagreement i.e. positive versus negative report without 
taking into account the different reporting categories.  The 
overall percentage of agreement ranges from 93.6% to 84.1% 
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and the inter-observer agreement with kappa ranged from 
0.783 to 0.480.  Four of the Consultant BMS had an inter-
observer agreement of good and the remaining two were 
classed as moderate.  The value of kappa is reliant on the 
number of categories and the fewer categories that there are 
tends to result in a higher kappa result which can be seen from 
the results above in Tables 9 (Watson and Petrie, 2010).   
Agreement between Negative, low grade CIN and high 
grade CIN + 
The following tables look at the agreement and disagreement 
rates broken down in to the classifications of negative, low 
grade CIN and high grade lesions including glandular neoplasia 
and cancer of each of the Consultant BMS reports compared to 
the final pathologists’ report using the kappa test.  This 
correlates with how a colposcopist would manage their patient 
on a two tier system of reporting and follows The Bethesda 
System (TBS) of reporting (Nayar and Wilbur, 2014).  
Reporting categories were grouped together as the following to 
facilitate the kappa analysis. 
 No CIN = 0 
 Low grade (LG) = CIN 1 (1) and probably low grade CIN 
(7) 
 High grade (HG) = CIN 2 (2), ungradeable CIN (4), 
equivocal CIN (5), probably high grade CIN (8), CIN 3 
(3), CGIN (9), high grade CIN/CGIN (10), stratified 
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mucin-producing intraepithelial lesion (SMILE) (12), low 
grade CIN/CGIN (13) and cancer (11)   
 
Tables 11 (K, A, N, B, M and P) Negative, low grade CIN 
and high grade CIN + 
     Consultant BMS K 
   Grade No CIN LG HG Total 
P
a
th
 No CIN 21 3 2 26 
LG 2 3 3 8 
HG 6 2 115 123 
Total 29 8 120 157 
Percentage agreement = 88.5%  κ = 0.689 (.95 CI 0.533 to 
0.824) 
     Consultant BMS A 
   Grade No CIN LG HG Total 
P
a
th
 No CIN 21 4 1 26 
LG 3 3 2 8 
HG 7 6 110 123 
Total 31 13 113 157 
Percentage agreement = 88.5%  κ = 0.633 (.95 CI 0.494 to 
0.772) 
     Consultant BMS N 
   Grade No CIN LG HG Total 
P
a
th
 No CIN 23 2 1 26 
LG 4 2 2 8 
HG 3 6 114 123 
Total 30 10 117 157 
Percentage agreement = 85.4%  κ = 0.699 (.95 CI 0.569 to 
0.830) 
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Consultant BMS B 
 Grade No CIN LG HG Total 
P
a
th
 No CIN 11 5 10 26 
LG 0 4 4 8 
HG 3 2 118 123 
Total 14 11 132 157 
Percentage agreement = 84.7%  κ = 0.527 (.95 CI 0.352 to 
0.701) 
Consultant BMS M 
 Grade No CIN LG HG Total 
P
a
th
 No CIN 17 8 1 26 
LG 2 3 3 8 
HG 3 7 113 123 
Total 22 18 117 157 
Percentage agreement = 84.7%  κ = 0.605 (.95 CI 0.460 to 
0.751) 
Consultant BMS P 
 Grade No CIN LG HG Total 
P
a
th
 No CIN 17 4 
5 26 
LG 3 0 5 8 
HG 13 8 102 123 
Total 33 12 112 157 
Percentage agreement = 75.8%  κ = 0.398 (.95 CI 0.232 to 
0.565) 
The overall percentage of agreement ranges from 88.5% 
to 75.8% and the inter-observer agreement with kappa 
ranged from 0.699 to 0.398.  Four of the Consultant BMS 
had an inter-observer agreement of good, one had 
moderate and the remaining Consultant BMS was 
classified as fair. 
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Agreement between Negative, CIN 1, CIN2, CIN 3 
with CGIN and Cancer Reports 
The following tables look at the agreement and 
disagreement rates broken down in to the classifications 
of negative, CIN including precancerous lesions of 
glandular neoplasia and cancer of each of the Consultant 
BMS reports compared to the final pathologists’ report 
using the kappa test.  
Reporting categories were grouped together as the 
following to facilitate the kappa analysis 
 No CIN = 0
 CIN 1 = CIN 1 (1) and probably low grade CIN (7)
 CIN 2 = CIN 2 (2), ungradeable CIN (4), equivocal
CIN (5) and probably high grade CIN (8)
 CIN 3 = CIN 3 (3), CGIN (9), high grade CIN/CGIN
(10), stratified mucin-producing intraepithelial
lesion (SMILE) (12) and low grade CIN/CGIN (13)
 Cancer = cancer (11)
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Tables 12 (K, A, N, B, M and P) Negative, CIN 1, CIN2, CIN 
3 and Cancer 
    Consultant BMS K 
    No CIN  CIN 1  CIN 2  CIN 3  Cancer  Total 
P
a
th
o
lo
g
is
t 
No CIN (0) 21 3 1 1 0 26 
CIN 1 (1,7) 2 3 1 2 0 8 
CIN 2 (2,4,5,8) 1 1 10 9 0 21 
CIN 3 
(3,9,10,12,13) 5 1 8 79 2 95 
Cancer (11) 0 0 0 2 5 7 
Total 29 8 20 93 7 157 
Percentage agreement = 75.2%  κ = 0.579 (.95 CI 0.464 to 
0.693) 
    Consultant BMS A 
    No CIN  CIN 1  CIN 2  CIN 3  Cancer  Total 
P
a
th
o
lo
g
is
t 
No CIN (0) 21 4 1 0 0 26 
CIN 1 (1,7) 3 3 1 1 0 8 
CIN 2 (2,4,5,8) 1 5 10 5 0 21 
CIN 3 
(3,9,10,12,13) 6 1 12 76 0 95 
Cancer (11) 0 0 1 4 2 7 
Total 31 13 25 86 2 157 
Percentage agreement = 71.3%  κ = 0.530 (.95 CI 0.414 to 
0.646) 
    Consultant BMS N 
    No CIN  CIN 1  CIN 2  CIN 3  Cancer  Total 
P
a
th
o
lo
g
is
t 
No CIN (0) 23 2 1 0 0 26 
CIN 1 (1,7) 4 2 2 0 0 8 
CIN 2 (2,4,5,8) 1 5 9 6 0 21 
CIN 3 
(3,9,10,12,13) 2 1 11 81 0 95 
Cancer (11) 0 0 0 5 2 7 
Total 30 10 23 92 2 157 
Percentage agreement = 74.5%  κ = 0.568 (.95 CI 0.453 to 
0.684) 
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    Consultant BMS B 
    No CIN  CIN 1  CIN 2  CIN 3  Cancer  Total 
P
a
th
o
lo
g
is
t 
No CIN (0) 11 5 4 6 0 26 
CIN 1 (1,7) 0 4 2 2 0 8 
CIN 2 (2,4,5,8) 0 0 7 14 0 21 
CIN 3 
(3,9,10,12,13) 2 2 7 82 2 95 
Cancer (11) 1 0 0 6 0 7 
Total 14 11 20 110 2 157 
Percentage agreement = 66.2%  κ = 0.375 (.95 CI 0.238 to 
0.512) 
    Consultant BMS M 
    No CIN  CIN 1  CIN 2  CIN 3  Cancer  Total 
P
a
th
o
lo
g
is
t 
No CIN (0) 17 8 0 1 0 26 
CIN 1 (1,7) 2 3 2 1 0 8 
CIN 2 (2,4,5,8) 0 3 13 5 0 21 
CIN 3 
(3,9,10,12,13) 3 4 11 76 1 95 
Cancer (11) 0 0 0 5 2 7 
Total 22 18 26 88 3 157 
Percentage agreement = 70.7%  κ = 0.519 (.95 CI 0.402 to 
0.636) 
    Consultant BMS P 
    No CIN  CIN 1  CIN 2  CIN 3  Cancer  Total 
P
a
th
o
lo
g
is
t 
No CIN (0) 17 4 5 0 0 26 
CIN 1 (1,7) 3 0 2 3 0 8 
CIN 2 (2,4,5,8) 2 5 10 4 0 21 
CIN 3 
(3,9,10,12,13) 10 3 16 66 0 95 
Cancer (11) 1 0 1 5 0 7 
Total 33 12 34 78 0 157 
Percentage agreement = 59.2%  κ = 0.355 (.95 CI 0.233 to 
0.476) 
The overall percentage of agreement ranges from 75.2% to 
59.2% and the inter-observer agreement with kappa ranged 
from 0.579 to 0.355.  The inter-observer agreement was 
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classified as moderate for four of the Consultant BMS and the 
rest were fair. 
Agreement between Negative, CIN 1, CIN2, CIN 3, 
glandular neoplasia and Cancer Reports 
The following tables look at the agreement and disagreement 
rates broken down in to the classifications of negative, CIN, 
glandular neoplasia and cancer of each of the Consultant BMS 
reports compared to the final pathologists’ report using the 
kappa test.  
Reporting categories were grouped together as the following to 
facilitate the kappa analysis 
 No CIN = 0 
 CIN 1 = CIN 1 (1) and probably low grade CIN (7) 
 CIN 2 = CIN 2 (2), ungradeable CIN (4), equivocal CIN 
(5) and probably high grade CIN (8)  
 CIN 3 = CIN 3 (3) 
 Glandular neoplasia (GN) = CGIN (9), high grade 
CIN/CGIN (10), stratified mucin-producing intraepithelial 
lesion (SMILE) (12) and low grade CIN/CGIN (13) 
 Cancer = cancer (11) 
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Tables 13 (K, A, N, B, M and P) Negative, CIN 1, CIN2, CIN 
3, GN and Cancer 
    Consultant BMS K 
P
a
th
o
lo
g
is
t 
  
No 
CIN   CIN 1  CIN 2   CIN 3   GN  
Cance
r   Total 
No CIN 21 3 1  0 1 0  26 
CIN 1  2 3 1 2 0  0  8 
CIN 2  1 1 10 9  0 0  21 
CIN 3 5 1 8 74  0 2 90 
GN   0 0  0  1 4  0 5 
Cancer   0 0   0 2  0 5 7 
Total 29 8 20 88 5 7 157 
Percentage agreement = 74.5%  κ = 0.593 (.95 CI 0.484 to 
0.702) 
    Consultant BMS A 
P
a
th
o
lo
g
is
t 
  
No 
CIN   CIN 1  CIN 2   CIN 3   GN  
Cance
r   Total 
No CIN 21 4 1 0 0 0 26 
CIN 1  3 3 1 1 0 0 8 
CIN 2  1 5 10 5 0 0 21 
CIN 3 6 1 12 71 0 0 90 
GN  0 0 0 0 5 0 5 
Cancer  0 0 1 4 0 2 7 
Total 31 13 25 81 5 2 157 
Percentage agreement = 71.3%  κ = 0.555 (.95 CI 0.445 to 
0.665) 
    Consultant BMS N 
P
a
th
o
lo
g
is
t 
  
No 
CIN   CIN 1  CIN 2   CIN 3   GN  Cancer   Total 
No CIN 23 2 1 0 0 0 26 
CIN 1  4 2 2 0 0 0 8 
CIN 2  1 5 9 6 0 0 21 
CIN 3 2 1 11 76 0 0 90 
GN  0 0 0 0 5 0 5 
Cancer  0 0 0 5 0 2 7 
Total 30 10 23 87 5 2 157 
Percentage agreement = 74.5%  κ = 0.593 (.95 CI 0.484 to 
0.702) 
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    Consultant BMS B 
P
a
th
o
lo
g
is
t 
  
No 
CIN   CIN 1  CIN 2   CIN 3   GN  Cancer   Total 
No CIN 11 5 4 3 3 0 26 
CIN 1  0 4 2 2 0 0 8 
CIN 2  0 0 7 14 0 0 21 
CIN 3 2 2 6 77 1 2 90 
GN  0 0 1 0 4 0 5 
Cancer  1 0 0 5 0 1 7 
Total 14 11 20 101 8 3 157 
Percentage agreement = 66.2%  κ = 0.431 (.95 CI 0.306 to 
0.556) 
    Consultant BMS M 
P
a
th
o
lo
g
is
t 
  
No 
CIN   CIN 1  CIN 2   CIN 3   GN  Cancer   Total 
No CIN 17 8 0 1 0 0 26 
CIN 1  2 3 2 1 0 0 8 
CIN 2  0 3 13 5 0 0 21 
CIN 3 5 1 8 74 0 2 90 
GN  1 0 0 1 3 0 5 
Cancer  0 0 0 5 0 2 7 
Total 25 15 23 87 3 4 157 
Percentage agreement = 70.1%  κ = 0.545 (.95 CI 0.433 to 
0.657) 
    Consultant BMS P 
P
a
th
o
lo
g
is
t 
  
No 
CIN   CIN 1  CIN 2   CIN 3   GN  
Cance
r   Total 
No CIN 17 4 5 0 0 0 26 
CIN 1  3 0 3 2 0 0 8 
CIN 2  2 5 10 4 0 0 21 
CIN 3 9 3 16 62 0 0 90 
GN  1 0 0 2 2 0 5 
Cancer  1 0 1 5 0 0 7 
Total 33 12 35 75 2 0 157 
Percentage agreement = 58.0%  κ = 0.360 (.95 CI 0.243 to 
0.478) 
The overall percentage of agreement ranges from 74.5% to 
58.0% and the inter-observer agreement with kappa ranged 
from 0.593 to 0.360.  There was an increased inter-observer 
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agreement even though there were more categories 
demonstrating that there was more agreement with the 
reporting categories which is not what you would expect with 
more options (Watson and Petrie, 2010). The inter-observer 
agreement was classified as moderate for five of the 
Consultant BMS and the final Consultant BMS was classified as 
fair.  
Margins 
On a LLETZ sample, there are three margins that need to be 
considered to report whether the lesion has been fully excised 
and these have been described previously (Figure 9).   
Tables 14 (K, A, N, B, M and P) Excisional margins 
    Consultant BMS K 
 Margin Endocervical Ectocervical 
Deep lateral 
margin 
    Pos  Neg  Pos  Neg  Pos Neg 
P
a
th
 Pos 12 2 31 12 0 1 
Neg 16 127 21 93 3 153 
Total 28 129 52 105 3 154 
Endocervical margins – percentage agreement = 88.5% κ = 0.514 
Ectocervical margins - percentage agreement = 79.0% κ = 0.504   
Deep lateral margins - percentage agreement = 97.5%* 
    Consultant BMS A 
 Margin Endocervical Ectocervical 
Deep lateral 
margin 
    Pos  Neg  Pos  Neg  Pos Neg 
P
a
th
 Pos 9 5 33 10 1 0 
Neg 11 132 22 92 4 152 
Total 20 137 55 102 5 152 
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Endocervical margins – percentage agreement = 89.8% κ = 0.474 
Ectocervical margins - percentage agreement = 79.6% κ = 0.529 
Deep lateral margins - percentage agreement = 97.5% κ = 0.326 
    Consultant BMS N 
 Margin Endocervical Ectocervical 
Deep lateral 
margin 
    Pos  Neg  Pos  Neg  Pos Neg 
P
a
th
 Pos 11 3 28 15 0 1 
Neg 6 137 5 109 2 154 
Total 17 140 33 124 2 155 
Endocervical margins – percentage agreement = 94.3% κ = 0.678 
Ectocervical margins - percentage agreement = 87.3% κ = 0.655   
Deep lateral margins - percentage agreement = 98.1%* 
    Consultant BMS B 
 Margin Endocervical Ectocervical 
Deep lateral 
margin 
    Pos  Neg  Pos  Neg  Pos Neg 
P
a
th
 Pos 10 4 23 20 0 1 
Neg 16 127 6 108 3 153 
Total 26 131 29 128 3 154 
Endocervical margins – percentage agreement = 87.3% κ = 0.434 
Ectocervical margins - percentage agreement = 83.4% κ = 0.537   
Deep lateral margins - percentage agreement = 97.5%* 
    Consultant BMS M 
 Margin Endocervical Ectocervical 
Deep lateral 
margin 
    Pos  Neg  Pos  Neg  Pos Neg 
P
a
th
 Pos 9 5 29 14 1 0 
Neg 16 127 13 101 5 151 
Total 25 132 42 115 6 151 
Endocervical margins – percentage agreement = 86.6% κ = 0.392 
Ectocervical margins - percentage agreement = 82.8% κ = 0.565   
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Deep lateral margins - percentage agreement = 96.8% κ = 0.278   
    Consultant BMS P 
 Margin Endocervical Ectocervical 
Deep lateral 
margin 
    Pos  Neg  Pos  Neg  Pos Neg 
P
a
th
 Pos 6 8 21 22 0 1 
Neg 6 137 8 106 2 154 
Total 12 145 29 128 2 155 
Endocervical margins – percentage agreement = 91.1% κ = 0.413 
Ectocervical margins - percentage agreement = 80.9% κ = 0.465  
Deep lateral margins - percentage agreement = 98.1%* 
*No kappa could be calculated as this data has an observed 
concordance which is smaller than mean-chance. 
Overall there were 14 cases that were positive at the 
endocervical margins and the ranges reported from the 
Consultant BMS were between 12 to 6 cases.   The overall 
percentage of agreement ranged from 87.3% to 79.0% with 
the inter-observer agreement with kappa ranged from 0.678 to 
0.392.  The high percentage of agreement is probably due to 
the fact that most of the margins were negative.  
There were 43 cases reported as having disease involved with 
the ectocervical margins and the ranges reported from the 
Consultant BMS were between 33 to 21 cases.  The overall 
percentage of agreement ranged from 94.3% to 86.6% with 
the inter-observer agreement with kappa ranged from 0.655 to 
0.465.  One Consultant BMS had good agreement with the 
other five Consultant BMS having moderate agreement. 
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There was only one case where the deep lateral margins were 
positive with the rest being negative, therefore a meaningful 
conclusion could not be made.  
Histological evidence of Human Papillomavirus (HPV) 
infection 
The following tables demonstrate the agreement between the 
pathologists and the Consultant BMS regarding the presence of 
HPV histologically or not in the LLETZ specimens. 
Tables 15 (K, A, N, B, M and P) Evidence of HPV infection 
    Consultant BMS K 
   HPV Pos  Neg  Total 
P
a
th
 Pos 106 6 112 
Neg 24 21 45 
Total 130 27 157 
HPV – percentage agreement = 80.9% κ = 0.469 
    Consultant BMS A 
   HPV Pos  Neg  Total 
P
a
th
 Pos 68 44 112 
Neg 20 25 45 
Total 88 69 147 
HPV – percentage agreement = 59.2% κ = 0.140 
    Consultant BMS N 
   HPV Pos  Neg  Total 
P
a
th
 Pos 86 26 112 
Neg 16 29 45 
Total 102 55 157 
HPV – percentage agreement = 73.2% κ = 0.387 
    Consultant BMS B 
   HPV Pos  Neg  Total 
P
a
th
 Pos 73 39 112 
Neg 12 33 45 
Total 85 72 157 
HPV – percentage agreement = 67.5% κ = 0.327 
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    Consultant BMS M 
   HPV Pos  Neg  Total 
P
a
th
 Pos 96 16 112 
Neg 29 16 45 
Total 125 32 157 
HPV – percentage agreement = 71.3% κ = 0.233 
    Consultant BMS P 
   HPV Pos  Neg  Total 
P
a
th
 Pos 93 19 112 
Neg 23 22 45 
Total 116 41 157 
HPV – percentage agreement = 73.2% κ = 0.328 
There were 112 samples that were reported with histological 
evidence of HPV infection.  The Consultant BMS agreement 
ranged from 80.9% to 59.2% with the kappa agreement from 
0.469 to 0.140.  One Consultant BMS demonstrated moderate 
agreement, four with fair agreement and one Consultant BMS 
had poor agreement.   
Discussion of Results 
Overall on the initial interpretation of the results, there would 
appear to be good inter-observer agreement between the 
Histopathologists final reports and the reports of the 
Consultant BMS as seen in Table 6 with most categories being 
rated as good agreement using the kappa classification.  This 
is at least as good and if not better than the Histopathologists’ 
performance in the literature searches.  Even when there were 
more reporting categories, the level of concordance was still 
moderate with the kappa classification.  This demonstrated 
that the Consultant BMS were able to identify the different 
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categories of CIN, CGIN and cancer with a moderate level of 
agreement.  
The inter-observer agreement from the original pilot site of 
two Consultant BMS of good was demonstrated in the larger 
study of Consultant BMS from the UK which was good and 
moderate agreement using the kappa coefficient.  The 
correlation was good despite there being many options of 
reporting categories to choose from which should have been 
restricted to more accurately reflect the recommended RCPath 
minimum data sets.  The extra reporting categories such as 
equivocal CIN, possibly low grade CIN and possibly high grade 
CIN were included to cover every possible reporting option for 
the Consultant BMS.  
The histological features associated with CIN are well-
described in text books and journals but the assessment is still 
subjective due to the continuous spectrum of the development 
of CIN through to cancer in the epithelium.  It is well-
documented that there is extensive inter-observer variation of 
Histopathologists when it comes to classifying CIN and the 
interpretation of CIN 1 in particular is poorly reproducible 
(Parker et al, 2002: Ismail et al, 1989: Creagh et al, 1995: 
Stoler et al, 2001: McCluggage et al, 1998: de Vet et al, 
1990).  The disagreement at the lower grades of CIN is due to 
the interpretation of koilocytes associated with an HPV 
infection which exaggerates the nuclear atypia.  There tends to 
be higher agreement with the diagnosis of no CIN and CIN 3 
(Robertson et al, 1989).   In this paper, the overall agreement 
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was κ = 0.34 which is classified as fair whereas looking at the 
same reporting categories, the overall agreement of the 
Consultant BMS was κ = 0.592 which is classified as moderate 
agreement.  There was still low agreement on whether 
histological features of HPV was present with a κ = 0.21.  Our 
overall agreement with features of HPV was κ = 0.314 so was 
comparable to experienced Histopathologists.   
On all the papers that were found where inter-observer 
variation was calculated, it was found to be fair only, which 
increased to moderate agreement if a two-tiered system of 
classification was used as in The Bethesda system 
(McCluggage et al, 1998).  Most of the papers reviewed were 
based on the interpretation of cervical biopsies rather than 
LLETZ specimens but the interpretation of CIN in all cervical 
histology sections follows the same classification guidelines 
that have been described previously.  As the papers were 
based on the diagnosis of cervical biopsies, the margins are 
not relevant so I was unable to determine how the Consultant 
BMS compared to the Histopathologists.   It was reassuring to 
find that my findings were comparable to the published data 
and the inter-observer agreements were consistent with the 
findings in my original pilot study.     
Consultant BMS B tended to overcall which probably reflected 
that he had the least histological experience of all the 
Consultant BMS that participated in this study. 
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Consultant BMS P had the lowest agreement compared to the 
rest of the Consultant BMS.  Although she came from a 
histology background, she was the least experienced 
Consultant BMS having only just passed the ASD plus she did 
not attend any of the training sessions.   
 
This would suggest that the training programme was an 
integral part of the study.  If such a training programme is 
taken forward, a training course covering the basics and 
‘pitfalls’ of reporting cervical samples should be a mandatory 
part of the programme.  Such a course provides the 
background, knowledge and a more equitable starting point for 
all the BMS going forward.  The self-assessment stage should 
be more formalised to aid with the development of bespoke 
training plans for future BMS undertaking the reporting of 
NHSCSP samples if a modular programme was developed.    
 
Consultant BMS B and P both missed the cervical cancer FIGO 
stage 1A1.  This case had a previous diagnostic biopsy which 
was diagnosed with cervical cancer and colposcopically 
presented as cancer.  In real practice such cases would be 
reviewed with a colleague and would be discussed at the 
Gynae cancer MDT.  
 
Where there were discrepant findings, the Consultant BMS 
paper reports were looked at more closely to see if they had 
difficulties with the diagnosis and what these were likely to be.  
As expected, the areas of concern were the typical pitfalls in 
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reporting cervical pathology such as when the epithelium was 
thin in atrophic cases, sections cross-cut so there was not the 
full thickness of epithelium, reactive and reparative changes 
and metaplastic squamous epithelium.  In real practice, such 
cases would be discussed with colleagues and extra tests 
would be requested such as immunocytochemical tests e.g. 
p16 to help with the diagnosis (NHS Cervical Screening 
Programme, 2012).    
 
Discrepancies in whether the margins were involved in cervical 
disease or not, were due to difficulties in interpreting tissue 
with diathermy artefact and where there were crypts with CIN 
close to the endocervical and deep lateral margins.  Again 
extra tests such a p16 and reviewing with colleagues would 
help in the diagnosis and this is the practice that would 
normally happen.  The NHSCSP has introduced HPV testing to 
assess test of cure (TOC) following the treatment by LLETZ 
and this has been found to be more sensitive for detecting 
residual disease or recurrence than cytology alone (Public 
Health England, 2016) . 
 
These pitfalls cause the same diagnostic difficulties for 
experienced Histopathologists and the same found with trainee 
pathologists.  It must be remembered that the Consultant BMS 
in this study were practicing independently and did not have 
access to any further tests or opinions.  They had to make a 
decision on the sections in front of them and they were 
possibly concentrating on getting the grade of intraepithelial 
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neoplasia right devoting less attention to the other clinically 
important parameters which is an indicator of inexperience. 
   
There was less agreement on the histological presence of HPV 
between the Consultant BMS and Gynae Histopathologists.  
This is in line with documented evidence of Consultant 
Histopathologists having little agreement between themselves 
as to whether histological features of HPV are present or not 
(Parker et al, 2002: Ismail et al, 1989: Creagh et al, 1995: 
Stoler et al, 2001: McCluggage et al, 1998: de Vet et al, 
1990).  This is because the features associated with HPV 
histologically are koilocytes and their interpretation is quite 
subjective as the criteria for diagnosis is not as clearly defined 
as for CIN.   
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Discussion 
LLETZ Reporting 
Essentially this study was to explore the possibilities of fast-
tracking Consultant BMS through to reporting selected 
specimens such as LLETZ to help with workloads in 
histopathology laboratories and to see if the results from the 
original pilot in 2010 could be replicated around the UK.  LLETZ 
specimens were chosen as they are clinically low risk as in the 
majority of cases there is a prior diagnosis, there is a lot of 
material to examine and they form a substantial part of the 
workload for a Gynae Histopathologist.  In my own laboratory 
we get approximately 500 LLETZ specimens a year.  It is 
acknowledged that the Consultant BMS reports were compared 
to the final reports of one of four Gynae Histopathologists 
rather than a consensus opinion which would have made the 
data more robust.  However, I felt this was negated by the fact 
that the STHFT Histopathologists were highly specialised in 
gynaecological pathology with extensive experience and they 
frequently review each other’s work as part of the work up for 
Gynae cancer MDTs, hence their reporting is remarkably 
consistent.  It is extremely rare for there to be any changes of 
opinion.  
As the LLETZ specimens were sequential and not preselected, 
they should reflect the workload in real practice.  As can be 
seen in Tables 7 and 8, STHFT tends to have more cases 
reported as CIN 2 + with 83% in 2018/18 compared to the 
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figures for England of 73.3% and in this study of 78.4%.  Our 
high grade rates may be higher due to practicing conservative 
management of women with CIN 2 and having a prior 
diagnostic cervical biopsy.  As stated earlier, STHFT is a cancer 
referral centre and could be another explanation for the higher 
rates.  The study had 78.4% reported as CIN 2 + which 
reflects a true and comparable workload as seen in England. 
On the thorough examination of the different reporting 
categories (Table 10 to 15), there was good agreement 
between the Consultant BMS and the final report that was 
generated as the ‘gold’ standard for correlation.  The 
concordance was good despite all the Consultant BMS 
reporting independently which would not happen in real 
practice as any discrepant findings or mismatches would be 
discussed with colleagues or extra tests would be requested to 
aid diagnosis.   
The analysis demonstrates that an experienced BMS could 
undertake the reporting of LLETZ specimens with minimal 
training, however it must be noted that the six Consultant BMS 
that participated in this preliminary study had substantial 
experience in their roles of reporting cervical cytology, 
however they had different histological experience which could 
explain some of the differences in their overall agreement.  For 
any future programmes, I would suggest that there was a 
more formal assessment prior to starting the training and with 
on-going assessment to gauge progress and to tailor any 
training plans moving forward.  In general, the overall 
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agreement was consistent from my original pilot study and 
carried across to the larger study.  I believe this demonstrates 
that there is potential to train this group of experienced BMS 
and ‘fast-track’ them through to reporting selected cases. 
Possibly an area of the study that could have been further 
explored would be the intra-observer variability of the 
individual Consultant BMS.  As the interpretation of histology 
and cytology is subjective, opinions can change on the same 
slides if they are presented to you at a different time.  This is 
known as intra-observer variability (McCluggage et al, 1998 
and Robertson et al, 1989).  If this study was repeated, I 
would suggest that 10% of cases would be recirculated for 
reporting to assess the consistency of reporting not only 
between the Consultant BMS but for them individually.  The 
results of the recirculated cases would be compared to rates 
found in the literature.  This would provide further evidence to 
say whether or not Consultant BMS reporting was at least 
equitable to Consultant Histopathologists and provide evidence 
on consistency.  If found to be comparable and consistency 
demonstrated, this would strengthen the evidence to suggest 
that Consultant BMS with suitable experience and competency 
could be ‘fast-tracked’ to report LLETZ.  I would also include 
the Gynae Histopathologists as part of this exercise to 
corroborate my assumption about the consistency of their 
reporting.  
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Proposal to the Conjoint Board  
To move this study forward, the report will be sent to the 
conjoint board of the RCPath and the IBMS.  The board should 
look at developing a training programme to look at the 
modular reporting of selected specimens such as LLETZ 
specimens with the possibility of expanding the remit to cover 
all specimens from the cervix.  As stated earlier, LLETZ 
specimens are part of the treatment regime and classified as 
clinically low risk as there is already an existing diagnosis in 
the majority of cases.  LLETZ samples are the best specimens 
to start to develop reporting skills as there is a large amount 
of material to examine and will enable the BMS to build their 
confidence.  As my study shows, a Consultant BMS can report 
these cases with reasonable accuracy after minimal training.  
As their confidence grows, other specimens can be introduced 
such as cervical biopsies and polyps.  LLETZ specimens and 
cervical biopsies are part of the NHSCSP with agreed national 
targets for their turnaround times (TATs).  These specimens 
would be suitable cases for qualified Consultant BMS to focus 
their reporting as they are time-sensitive.   
I would suggest that the training programme follows the 
template of the ASD programme for Histopathology reporting.  
An initial interview should take place to assess the suitability of 
the prospective BMS.  As part of this interview, there should be 
a more formal assessment with a questionnaire and slide test 
to gauge their experience and their commitment to the 
training programme.  There would be an agreed number of 
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cases to be reported and recorded in a portfolio with their 
supervising Histopathologist.  By completing a portfolio any 
training issues would be identified such as reporting CIN at the 
margins or grading problems.  The BMS should perform audits 
comparing their findings to the final report and the colposcopic 
impression.  They should write up interesting cases as part of 
their portfolio presentation discussing how the use of 
immunocytochemical tests helped them make the final 
diagnosis.  During their training, they would be expected to 
attend the Colposcopy MDTs and present the histology for the 
cervical specimens under the supervision of their named 
Histopathologist.  These meetings and presentations would be 
recorded in their portfolio.  The portfolio would be sent to the 
RCPath and IBMS Conjoint Board for assessment and if the 
portfolio passed this stage there would be an exit examination 
which would demonstrate that the BMS had reached the 
necessary standard to proceed with the next stage of reporting 
– equivalent to stage D.  This final stage would be the 
consolidation period where the BMS would start to report 
independently.  During this probationary period, the 
supervising Histopathologist would review a selection of cases 
until they were confident that the BMS was deemed competent 
to report independently.   
I would anticipate that this module should take a year to 
complete but would depend on their previous experience.  
Other modules could be developed or expanded to cover 
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different areas of gynaecological pathology such as reporting 
benign hysterectomy specimens and endometrial samples.   
This training programme should be more achievable and 
acceptable to the BMS going through the process rather than 
the four years at least, associated with the current ASD for 
Histopathology reporting.  This should provide more timely 
benefits to Trusts that are struggling with the recruitment of 
Histopathologists and allows the Histopathologists to focus on 
the more complex cases.  BMS going through this process 
should still have protected time however this would still be less 
of a burden on departments when compared to the 
commitment associated with the full ASD Gynaecological 
Histopathology reporting programme.  There are only a few 
BMS that have successfully completed the ASD and as stated 
earlier, there is a high dropout rate probably due to the time 
commitment of a minimum of four years and the lack of 
protected time.  There was a dropout rate of a third in this 
study reiterating that any prospective BMS must have the time 
and commitment to complete the programme.  I believe that if 
this reporting post was introduced, it would need to be 
properly resourced with protected time, workplace support and 
appropriate grading.        
External Quality Assurance (EQA) Scheme   
The NHSCSP sets performance standards for all the reporting 
aspects of the programme.  There are national returns called 
KC61 for cervical cytology and KC65 for colposcopy which sets 
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the key performance indicators (KPIs).  Such standards 
measure TATs, reporting profiles and minimum numbers 
cytologists should screen/report or new women colposcopy 
clinicians should see.  As part of these performance standards, 
cervical cytology has a dedicated external quality assurance 
(EQA) scheme where slides are distributed to test everybody 
who screens and reports slides for the NHSCSP.  If any slides 
are missed, there is a poor performance protocol that gives the 
manager guidance on methods to monitor improvement and 
information on any remedial training if required.    
There is currently no EQA scheme for histology specimens as 
part of the NHSCSP although there are guidelines as to how to 
report these for the programme (NHS Cervical Screening 
Programme, 2012).  A cervical histology EQA scheme should 
be introduced to ensure a consistent approach across the 
programme and all practitioners that are reporting are 
operating at a minimum quality standard.  Even though I have 
said that Histopathologists only have fair agreement, the cases 
would need to be carefully selected based on consensus 
reporting prior to distribution.  This would provide confidence 
to the NHSCSP and the public about reporting standards for 
cervical biopsies and LLETZ as part of the programme.  There 
have been discussions about the possibility of introducing such 
a scheme for histology samples reported in the NHSCSP but 
there has been a reluctance to move this forward.  This is 
because Gynae Histopathologists already take part in a 
gynaecological pathology EQA which covers all sorts of 
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specimens as well as LLETZ and cervical biopsies.  The 
introduction a NHSCSP EQA scheme for cervical biopsies and 
LLETZ should be introduced to monitor standards of reporting 
and would complement the introduction of Consultant BMS 
reporting.    
Cost Benefits 
The Royal College has produced guidelines for staffing 
histopathology laboratories and we are waiting for the updated 
version five (Royal College of Pathology, 2015).  The document 
provides guidance to ensure that there are safe and 
appropriate staffing levels of Histopathologists to cover 
workloads and to help with job planning.  The document uses a 
point system and points are awarded for all aspects of the 
Histopathologists’ workloads including time for dissection, 
microscopy reporting and supervision of trainee pathologists 
and/or BMS. 
Medical consultants have job plans and these are split into four 
hour sessions known as programmed activities (PAs).  There 
are four types of PAs – direct clinical care (DCC), supporting 
professional activities (SPA), additional NHS responsibilities 
and external duties.  To work out staffing levels based on 
workloads, points are awarded to the time taken for the 
specimens ranging from 1 point for 1 to 5 minutes up to 12 
points for cases over 50 minutes.   
In the RCPath document a LLETZ specimen attracts 3 points 
and one PA of direct clinical care (DCC) equates to 36 points 
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per four hour session.  In this document is states that time 
should be allowed for other commitments such as enquiries, 
extra tests such as immunocytochemistry and supplementary 
reports associated with more complex cases.  If we allow 30 
points for direct reporting, a Histopathologist should be able to 
report 10 LLETZ cases per PA.  Taking the midpoint of the 
medical consultant’s pay scale, the annual cost for a NHS Trust 
is £11,900 per PA.  This equates to each PA costing £230 and 
therefore the cost of reporting each LLETZ specimen is 
approximately £23.    
Looking at mid-point of the Agenda for Change pay scale for 8c 
which is the grade most Consultant BMS are appointed to, the 
salary is £64,670.  The equivalent cost of a PA for a BMS on 8c 
would be £132.  This means that the costs of a Consultant 
BMS reporting a LLETZ specimen would be £13.20 which is 
43% cheaper than a Histopathologist.   
Future Developments  
Currently all cervical specimens deemed as part of the NHS 
cervical screening programme are assessed down the 
microscope with glass slides.  As technology has developed, 
digital pathology has come to the forefront where the 
traditional glass slides are scanned to generate a digital image 
that can be stored electronically and viewed on a high 
resolution monitor known as the virtual microscope.  This 
allows images to be shared electronically with colleagues 
anywhere in the world and will be able to help with backlog 
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reporting  Digital marks can be left on the images to get a 
second opinion from any experts worldwide instantaneously.  
External quality assurance schemes will enable slides to be 
transported electronically rather than be posted without the 
inherent risk of breakage.  Good examples of teaching material 
can also be captured electronically without having to request 
extra sections or keeping the original slides.  The limitation 
with these images at the moment in the UK is that they are 
huge and most NHS internet connections do not have the 
sufficient speed and width to accommodate them. 
I would not support using my method of training Consultant 
BMS as it is a logistical and expensive procedure moving slides 
around the country for training plus there is a risk of slides 
breaking.  There is the advantage that all the Consultant BMS 
are looking at the same slides so they can be assessed against 
their peers and their training can be controlled.  This system of 
training could be reviewed once digital pathology and the 
infrastructure to support this is fit for purpose. 
Once the Consultant BMS are competent to practice 
independently and with the support of the NHSCSP, RCPath 
and IBMS they could provide a valuable resource to help with 
reporting backlogs of work associated with the cervical 
screening programme.  This would be easier to facilitate once 
it is acceptable for specimens as part of the NHSCSP to be 
reported digitally.   
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looking at other areas of the Histopathology workload where a 
module structure could be introduced.    
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Conclusion 
This report provides a ‘snap shot’ of histology reporting of 
selected samples in this case LLETZ specimens for 
appropriately experienced BMS with minimal training.  As 
stated earlier, there is a crisis now facing histopathology 
departments with the chronic lack of Histopathologists and 
although there are plans to increase the number of 
Histopathologists, this is going to take time.  Due to the 
consolidation of cervical screening centres in England, there 
will be a number of Consultant BMS with extensive microscopy 
skills who will not be in a position to relocate and these skills 
will be lost to the service.  This study provides an option where 
suitably experienced Consultant BMS can be ‘fast-tracked’ 
through an approved training programme to meet the needs of 
the service in a more timely fashion and provide a cost-
effective solution.   
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Glossary 
Acronym Full Wording 
ABMSP Advanced biomedical scientist practitioner 
ASD Advanced specialist diploma 
BMS Biomedical scientist 
CIN Cervical intraepithelial neoplasia 
CGIN Cervical glandular intraepithelial neoplasia 
DOH Department of Health 
EQA External Quality Assurance 
FIGO 
International Federation of Gynaecology and 
Obstetrics 
GIT Gastrointestinal tract 
HCPC Health and Care Professionals Council 
H&E Haematoxylin and eosin 
HSIL High grade squamous intraepithelial lesion  
HPV Human Papilloma Virus 
HPV PS HPV primary screening 
IBMS Institute of Biomedical Science 
IAC International Academy of Cytology 
LLETZ Large loop excision of transformation zone 
LBC Liquid based cytology 
LSIL Low grade squamous intraepithelial lesion 
MDT Multi-Disciplinary Team 
NHS National Health Service 
NHS CSP NHS Cervical Screening Programme 
NHSE NHS England 
NICE 
National Institute for Health and Clinical 
Excellence 
NSC National screening committee 
NBF Neutral buffered formalin 
PHE Public Health England 
QA Quality Assurance 
QC Quality Control 
REC Research Ethics Committee 
RCPath Royal College of Pathologists 
RHH Royal Hallamshire Hospital 
SIL Squamous intraepithelial lesion 
STH FT 
Sheffield Reaching Hospitals NHS Foundation 
Trust 
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TOC Test of cure 
TBS The Bethesda System 
TATS Turnaround Times 
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